

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in de-intensification of... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-447/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-447" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in de-intensification of radiotherapy in elderly cancer patients" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in de-intensification of radiotherapy in elderly cancer patients.">
            <meta name="og:description" content="Read the latest article version by Isacco Desideri, Viola Salvestrini, Lorenzo Livi, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="23282">
            <meta name="article-id" content="21151">
            <meta name="dc.title" content="Recent advances in de-intensification of radiotherapy in elderly cancer patients">
            <meta name="dc.description" content="Cancer in the elderly remains an evolving issue and a health challenge. Several improvements in the radiotherapy field allow the delivery of higher doses/fractions with a safe toxicity profile, permitting the reduction of radiation treatment protocols in the elderly. Regarding breast, prostate, and lung cancer, the under-representation of older patients in clinical trials limits the extension of treatment recommendations to elderly patients in routine clinical practice. Among the feasible alternatives to standard whole breast radiotherapy (WBRT) in older patients are shorter courses using higher hypofractionation (HF) and accelerated partial breast irradiation (APBI). The boost continues to be used in women at high risk of local recurrence but is less widely accepted for women at lower risk and patients over 70 years of age. Regarding prostate cancer, there are no published studies with a focus on the elderly. Current management decisions are based on life expectancy and geriatric assessment. Regimens of HF and ultra-HF protocols are feasible strategies for older patients. Several prospective non-randomized studies have documented the safe delivery of ultra-HF for patients with localized prostate cancer, and multiple phase III trials and meta-analyses have confirmed that the HF regimen should be offered with similar acute toxicity regardless of patient age and comorbidity. A recent pooled analysis from two randomized trials comparing surgery to stereotactic body radiation therapy (SBRT) in older adult patients with early stage non-small cell lung cancer did show comparable outcomes between surgery and SBRT. Elderly cancer patients are significantly under-represented in all clinical trials. Thus, the inclusion of older patients in clinical studies should be strongly encouraged to strengthen the evidence base for this age group. We suggest that the creation of oncogeriatric coordination units may promote individualized care protocols, avoid overtreatment with aggressive and unrecommended therapies, and support de-escalating treatment in elderly cancer patients.">
            <meta name="dc.subject" content="elderly, radiotherapy, de-intensification, prostate cancer, breast cancer, lung cancer">
            <meta name="dc.creator" content="Desideri, Isacco">
            <meta name="dc.creator" content="Salvestrini, Viola">
            <meta name="dc.creator" content="Livi, Lorenzo">
            <meta name="dc.date" content="2020/05/27">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.21151.1">
            <meta name="dc.source" content="F1000Research 2020 9:447">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="elderly">
            <meta name="prism.keyword" content="radiotherapy">
            <meta name="prism.keyword" content="de-intensification">
            <meta name="prism.keyword" content="prostate cancer">
            <meta name="prism.keyword" content="breast cancer">
            <meta name="prism.keyword" content="lung cancer">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/05/27">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="447">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.21151.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-447">
            <meta name="citation_title" content="Recent advances in de-intensification of radiotherapy in elderly cancer patients">
            <meta name="citation_abstract" content="Cancer in the elderly remains an evolving issue and a health challenge. Several improvements in the radiotherapy field allow the delivery of higher doses/fractions with a safe toxicity profile, permitting the reduction of radiation treatment protocols in the elderly. Regarding breast, prostate, and lung cancer, the under-representation of older patients in clinical trials limits the extension of treatment recommendations to elderly patients in routine clinical practice. Among the feasible alternatives to standard whole breast radiotherapy (WBRT) in older patients are shorter courses using higher hypofractionation (HF) and accelerated partial breast irradiation (APBI). The boost continues to be used in women at high risk of local recurrence but is less widely accepted for women at lower risk and patients over 70 years of age. Regarding prostate cancer, there are no published studies with a focus on the elderly. Current management decisions are based on life expectancy and geriatric assessment. Regimens of HF and ultra-HF protocols are feasible strategies for older patients. Several prospective non-randomized studies have documented the safe delivery of ultra-HF for patients with localized prostate cancer, and multiple phase III trials and meta-analyses have confirmed that the HF regimen should be offered with similar acute toxicity regardless of patient age and comorbidity. A recent pooled analysis from two randomized trials comparing surgery to stereotactic body radiation therapy (SBRT) in older adult patients with early stage non-small cell lung cancer did show comparable outcomes between surgery and SBRT. Elderly cancer patients are significantly under-represented in all clinical trials. Thus, the inclusion of older patients in clinical studies should be strongly encouraged to strengthen the evidence base for this age group. We suggest that the creation of oncogeriatric coordination units may promote individualized care protocols, avoid overtreatment with aggressive and unrecommended therapies, and support de-escalating treatment in elderly cancer patients.">
            <meta name="citation_description" content="Cancer in the elderly remains an evolving issue and a health challenge. Several improvements in the radiotherapy field allow the delivery of higher doses/fractions with a safe toxicity profile, permitting the reduction of radiation treatment protocols in the elderly. Regarding breast, prostate, and lung cancer, the under-representation of older patients in clinical trials limits the extension of treatment recommendations to elderly patients in routine clinical practice. Among the feasible alternatives to standard whole breast radiotherapy (WBRT) in older patients are shorter courses using higher hypofractionation (HF) and accelerated partial breast irradiation (APBI). The boost continues to be used in women at high risk of local recurrence but is less widely accepted for women at lower risk and patients over 70 years of age. Regarding prostate cancer, there are no published studies with a focus on the elderly. Current management decisions are based on life expectancy and geriatric assessment. Regimens of HF and ultra-HF protocols are feasible strategies for older patients. Several prospective non-randomized studies have documented the safe delivery of ultra-HF for patients with localized prostate cancer, and multiple phase III trials and meta-analyses have confirmed that the HF regimen should be offered with similar acute toxicity regardless of patient age and comorbidity. A recent pooled analysis from two randomized trials comparing surgery to stereotactic body radiation therapy (SBRT) in older adult patients with early stage non-small cell lung cancer did show comparable outcomes between surgery and SBRT. Elderly cancer patients are significantly under-represented in all clinical trials. Thus, the inclusion of older patients in clinical studies should be strongly encouraged to strengthen the evidence base for this age group. We suggest that the creation of oncogeriatric coordination units may promote individualized care protocols, avoid overtreatment with aggressive and unrecommended therapies, and support de-escalating treatment in elderly cancer patients.">
            <meta name="citation_keywords" content="elderly, radiotherapy, de-intensification, prostate cancer, breast cancer, lung cancer">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Isacco Desideri">
            <meta name="citation_author_institution" content="Department of Experimental and Clinical Biomedical Sciences Biochemistry, Radiotherapy Unit, University of Florence, Florence, Italy">
            <meta name="citation_author" content="Viola Salvestrini">
            <meta name="citation_author_institution" content="Department of Experimental and Clinical Biomedical Sciences Biochemistry, Radiotherapy Unit, University of Florence, Florence, Italy">
            <meta name="citation_author" content="Lorenzo Livi">
            <meta name="citation_author_institution" content="Department of Experimental and Clinical Biomedical Sciences Biochemistry, Radiotherapy Unit, University of Florence, Florence, Italy">
            <meta name="citation_publication_date" content="2020/05/27">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="447">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.21151.1">
            <meta name="citation_firstpage" content="447">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-447/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-447.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=23282 /> <input type=hidden id=articleId name=articleId value=21151 /> <input type=hidden id=xmlUrl value="/articles/9-447/v1/xml"/> <input type=hidden id=xmlFileName value="-9-447-v1.xml"> <input type=hidden id=article_uuid value=f86837c3-78fb-408d-8711-cbe03f5de89f /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in de-intensification of radiotherapy in elderly cancer patients"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.21151.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.21151.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-447"
  },
  "headline": "Recent advances in de-intensification of radiotherapy in elderly cancer patients",
  "datePublished": "2020-05-27T09:03:55",
  "dateModified": "2020-05-27T09:03:55",
  "author": [
    {
      "@type": "Person",
      "name": "Isacco Desideri"
    },    {
      "@type": "Person",
      "name": "Viola Salvestrini"
    },    {
      "@type": "Person",
      "name": "Lorenzo Livi"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Cancer in the elderly remains an evolving issue and a health challenge. Several improvements in the radiotherapy field allow the delivery of higher doses/fractions with a safe toxicity profile, permitting the reduction of radiation treatment protocols in the elderly. Regarding breast, prostate, and lung cancer, the under-representation of older patients in clinical trials limits the extension of treatment recommendations to elderly patients in routine clinical practice. Among the feasible alternatives to standard whole breast radiotherapy (WBRT) in older patients are shorter courses using higher hypofractionation (HF) and accelerated partial breast irradiation (APBI). The boost continues to be used in women at high risk of local recurrence but is less widely accepted for women at lower risk and patients over 70 years of age. Regarding prostate cancer, there are no published studies with a focus on the elderly. Current management decisions are based on life expectancy and geriatric assessment. Regimens of HF and ultra-HF protocols are feasible strategies for older patients. Several prospective non-randomized studies have documented the safe delivery of ultra-HF for patients with localized prostate cancer, and multiple phase III trials and meta-analyses have confirmed that the HF regimen should be offered with similar acute toxicity regardless of patient age and comorbidity. A recent pooled analysis from two randomized trials comparing surgery to stereotactic body radiation therapy (SBRT) in older adult patients with early stage non-small cell lung cancer did show comparable outcomes between surgery and SBRT. Elderly cancer patients are significantly under-represented in all clinical trials. Thus, the inclusion of older patients in clinical studies should be strongly encouraged to strengthen the evidence base for this age group. We suggest that the creation of oncogeriatric coordination units may promote individualized care protocols, avoid overtreatment with aggressive and unrecommended therapies, and support de-escalating treatment in elderly cancer patients."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-447/v1",
            "name": "Recent advances in de-intensification of radiotherapy in elderly cancer..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in de-intensification of radiotherapy in elderly cancer... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=23282 data-id=21151 data-downloads="" data-views="" data-scholar="10.12688/f1000research.21151.1" data-recommended="" data-doi="10.12688/f1000research.21151.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-447/v1/pdf?article_uuid=f86837c3-78fb-408d-8711-cbe03f5de89f" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-21151-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-21151-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-21151-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Desideri I, Salvestrini V and Livi L. Recent advances in de-intensification of radiotherapy in elderly cancer patients [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):447 (<a class=new-orange href="https://doi.org/10.12688/f1000research.21151.1" target=_blank>https://doi.org/10.12688/f1000research.21151.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-21151-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=21151 id=track-article-signin-21151 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/21151?target=/articles/9-447/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=23282 /> <input name=articleId type=hidden value=21151 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in de-intensification of radiotherapy in elderly cancer patients</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Isacco Desideri,&nbsp;</span><span class=""><a href="mailto:salvestrini.viola@gmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Viola Salvestrini</span></a>,&nbsp;</span><span class="">Lorenzo Livi<a href="https://orcid.org/0000-0002-7755-9422" target=_blank id=author-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-7755-9422</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Isacco Desideri,&nbsp;</span><span class=""><a href="mailto:salvestrini.viola@gmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Viola Salvestrini</span></a>,&nbsp;</span><span class="">Lorenzo Livi<a href="http://orcid.org/0000-0002-7755-9422" target=_blank id=mauthor-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-7755-9422</div></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 27 May 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.21151.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Experimental and Clinical Biomedical Sciences Biochemistry, Radiotherapy Unit, University of Florence, Florence, Italy<br/> <p> <div class=margin-bottom> Isacco Desideri <br/> <span>Roles: </span> Conceptualization, Data Curation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Viola Salvestrini <br/> <span>Roles: </span> Data Curation, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Lorenzo Livi <br/> <span>Roles: </span> Conceptualization, Supervision, Validation </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=67017-62932></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=67018-62931></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Cancer in the elderly remains an evolving issue and a health challenge. Several improvements in the radiotherapy field allow the delivery of higher doses/fractions with a safe toxicity profile, permitting the reduction of radiation treatment protocols in the elderly. Regarding breast, prostate, and lung cancer, the under-representation of older patients in clinical trials limits the extension of treatment recommendations to elderly patients in routine clinical practice. Among the feasible alternatives to standard whole breast radiotherapy (WBRT) in older patients are shorter courses using higher hypofractionation (HF) and accelerated partial breast irradiation (APBI). The boost continues to be used in women at high risk of local recurrence but is less widely accepted for women at lower risk and patients over 70 years of age. Regarding prostate cancer, there are no published studies with a focus on the elderly. Current management decisions are based on life expectancy and geriatric assessment. Regimens of HF and ultra-HF protocols are feasible strategies for older patients. Several prospective non-randomized studies have documented the safe delivery of ultra-HF for patients with localized prostate cancer, and multiple phase III trials and meta-analyses have confirmed that the HF regimen should be offered with similar acute toxicity regardless of patient age and comorbidity. A recent pooled analysis from two randomized trials comparing surgery to stereotactic body radiation therapy (SBRT) in older adult patients with early stage non-small cell lung cancer did show comparable outcomes between surgery and SBRT. Elderly cancer patients are significantly under-represented in all clinical trials. Thus, the inclusion of older patients in clinical studies should be strongly encouraged to strengthen the evidence base for this age group. We suggest that the creation of oncogeriatric coordination units may promote individualized care protocols, avoid overtreatment with aggressive and unrecommended therapies, and support de-escalating treatment in elderly cancer patients. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> elderly, radiotherapy, de-intensification, prostate cancer, breast cancer, lung cancer </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Viola Salvestrini (<a href="mailto:salvestrini.viola@gmail.com">salvestrini.viola@gmail.com</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Viola Salvestrini </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Desideri I <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Desideri I, Salvestrini V and Livi L. Recent advances in de-intensification of radiotherapy in elderly cancer patients [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):447 (<a href="https://doi.org/10.12688/f1000research.21151.1" target=_blank>https://doi.org/10.12688/f1000research.21151.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 27 May 2020, <b>9</b>(F1000 Faculty Rev):447 (<a href="https://doi.org/10.12688/f1000research.21151.1" target=_blank>https://doi.org/10.12688/f1000research.21151.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 27 May 2020, <b>9</b>(F1000 Faculty Rev):447 (<a href="https://doi.org/10.12688/f1000research.21151.1" target=_blank>https://doi.org/10.12688/f1000research.21151.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d34928e157>Introduction</h2><p class="" id=d34928e160>Cancer in the elderly population remains an evolving issue and a health challenge. Radiotherapy (RT) is an essential element of the management of older cancer patients<sup><a href="#ref-1">1</a></sup>. It is common knowledge to assess these patients based on functional status and not only on chronological age. Although the exact definition of the age group is controversial, we can define elderly patients as persons with a chronological age of 65 years and above<sup><a href="#ref-2">2</a></sup>. Whenever a decision has to be made regarding the intensity of treatment for elderly patients suffering with cancer, efforts should be focused on anticipating patients’ frailties leading to potentially harmful treatment side effects in this subset of patients. Comprehensive geriatric assessment (CGA) has been introduced by geriatricians to predict morbidity and mortality in elderly cancer patients. As the CGA requires the presence of a dedicated geriatrician and it is time-consuming, a number of different tools have been proposed as CGA surrogates to the scientific community. In a comprehensive review, the G8 was the most robust test, and it can be completed in less than 5 minutes<sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a></sup>.</p><p class="" id=d34928e178>In an attempt to preserve elderly cancer patients’ quality of life with regard to toxicity while maintaining a curative intent, a tuning of treatment aggressiveness is a particularly attractive subject in this context. De-intensification of radiation treatment remains an unresolved problem. Novel RT approaches enable high doses to be administered safely to the tumor whilst lowering exposure to nearby critical organs. This has resulted in shorter curative and palliative protocols<sup><a href="#ref-5">5</a></sup>. Technological advances, such as intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT), have improved radiation effectiveness while reducing morbidity and improving daily patients’ set up and immobilization<sup><a href="#ref-6">6</a>–<a href="#ref-8">8</a></sup>.</p><p class="" id=d34928e192>Among improvements in RT delivery, efforts have been made to reduce toxicity related to organ motion, especially in the case of thoracic irradiation. Techniques limiting respiratory motion, such as controlled breath-hold and abdominal compression, are a viable option in the general cancer population; unfortunately, these approaches are frequently not tolerated by elderly patients. A feasible alternative could be the incorporation of 4D planning computed tomography (CT) scans. Other strategies to compensate for motion include respiratory gating, adjustment of field sizes, and tumor tracking<sup><a href="#ref-9">9</a></sup>. Ultimately, precise target definition allows better delineation of organs at risk and supports the delivery of higher doses/fractions with a safe toxicity profile, permitting the reduction of radiation treatment protocols in the elderly.</p><p class="" id=d34928e199>Despite the fact that the elderly are a growing significant proportion of cancer patients, they remain under-represented in most clinical studies of RT with limited level I evidence in this population. Regarding breast, prostate, and lung cancer, this under-representation of elderly patients in clinical trials limits the extension of treatment recommendations to this patient group in routine clinical practice. The aim of our work is to explain the principal strategies of de-intensification in elderly patients affected by different primary cancers obtainable through the adoption of these new RT techniques with a focus on curative indications.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d34928e205>Breast cancer</h2><p class="" id=d34928e208>Breast cancer is the most prevalent disease in elderly women and the primary cause of death. Management is undefined in this patient group because elderly women are rarely included in relevant clinical trials<sup><a href="#ref-10">10</a></sup>. The gold standard for all patients affected by early invasive breast cancer (IBC) is whole breast irradiation (WBI) following breast-conserving surgery (BCS). The Oxford overview regarding trials on BCS with or without WBI highlights a decrease in first recurrence in “low-risk” older patients; even if comparing the elderly population (70 years of age or older) with younger patients, the absolute 10-year risk reduction of any locoregional or distant relapse is lower<sup><a href="#ref-11">11</a></sup>. A randomized study (the CALGB 9343 trial) evaluating 636 older women (aged 70 years) with IBC treated with BCS and adjuvant tamoxifen with or without WBI showed an absolute decrease in ipsilateral breast tumor recurrence (IBTR) rate of 3% at 5-year follow-up and of 7% in the RT group<sup><a href="#ref-12">12</a></sup>.</p><p class="" id=d34928e223>Among the feasible treatment modalities for older patients, shorter courses using hypofractionated (HF) schedules are available. Several randomized controlled trials (RCTs) have pointed out similar rates of local control and late toxicity in terms of cosmesis using heterogeneous HF-RT regimens after BCS<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. In light of recent findings, the 2018 ASTRO WBI guidelines endorse HF-WBI in patients with breast cancer irrespective of their age, the stage of their tumor, and whether or not they have undergone chemotherapy<sup><a href="#ref-15">15</a></sup>.</p><p class="" id=d34928e237>The rationale for the delivery of boost to the tumor bed in patients receiving BCS and WBI comes from evidence that local relapse is commonly found at the site of the primary tumor. In detail, 44 to 90% of local recurrences occurred in proximity of the tumor bed<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>. Several randomized studies compared irradiation with or without tumor bed boost in a timeframe of about 10 years (<a href="#T1">Table 1</a>)<sup><a href="#ref-18">18</a>–<a href="#ref-21">21</a></sup>. Findings obtained from these five studies confirmed that delivery of boost after WBI offered a benefit in terms of decrease in local relapses, without any detrimental effect on survival or other outcomes<sup><a href="#ref-22">22</a></sup>. Furthermore, the impact of bed boost diluted as the patient’s age increased<sup><a href="#ref-21">21</a></sup>. Among reasons for questioning the boost, we identified higher treatment costs and potentially adverse events. The size of the absolute benefit of the boost dose for tumor control decreases with increasing age; this limited gain in local control in older patients should be weighed against the increase in risk of late adverse effects such as fibrosis<sup><a href="#ref-21">21</a>,<a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>. According to current standards, omitting a tumor bed boost is suggested with conditional recommendation strength and moderate quality of evidence in patients with IBC who are older than 70, are hormone receptor positive, and have tumors of low or intermediate grade resected with widely negative (≥2 mm) margins<sup><a href="#ref-15">15</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Phase III trials investigating tumor bed boost after breast-conserving surgery.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d34928e291 class=n-a></a><thead><a name=d34928e293 class=n-a></a><tr><a name=d34928e295 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e297 class=n-a></a>Trial</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e300 class=n-a></a>Study<br class=br>period</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e305 class=n-a></a>Study patients,<br class=br>overall (elderly)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e310 class=n-a></a>Elderly patients<br class=br>(%)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e315 class=n-a></a>RT technique,<br class=br>study design</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e321 class=n-a></a>OS rates</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e324 class=n-a></a>LR rates</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e327 class=n-a></a>Subgroup<br class=br>analysis in<br class=br>elderly</th></tr></thead><tbody><a name=d34928e336 class=n-a></a><tr><a name=d34928e338 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e339 class=n-a></a><b>EORTC<sup><a href="#ref-21">21</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e346 class=n-a></a>1989–1996</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e349 class=n-a></a>5,318 (1,732)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e352 class=n-a></a>32.6 (&gt;60 years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e355 class=n-a></a>EBRT; LDR<br class=br>brachytherapy<a href="#TFN1">°</a><br class=br>WBI vs. WBI+boost</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e364 class=n-a></a>At 20 years:<br class=br>61.1% (WBI)<br class=br>vs. 59.7%<br class=br>(WBI+boost);<br class=br><i>P</i> = 0.33</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e378 class=n-a></a>At 10 years:<br class=br>13% (WBI)<br class=br>vs. 9%<br class=br>(WBI+boost);<br class=br><i>P</i> &lt;0.0001</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e391 class=n-a></a>Yes</td></tr><tr><a name=d34928e394 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e395 class=n-a></a><b>Lyon<sup><a href="#ref-18">18</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e402 class=n-a></a>1986–1992</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e405 class=n-a></a>1,024 (272)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e408 class=n-a></a>26.5 (&gt;61 years) </td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e411 class=n-a></a>EBRT<a href="#TFN1">°</a> WBI vs.<br class=br>WBI+boost</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e419 class=n-a></a>At 5 years:<br class=br>90.4% (WBI)<br class=br>vs. 92.9%<br class=br>(WBI+boost);<br class=br><i>P</i> = 0.24</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e433 class=n-a></a>At 3.3 years:<br class=br>4.5% (WBI)<br class=br>vs. 3.6%<br class=br>(WBI+boost);<br class=br><i>P</i> = 0.44</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e446 class=n-a></a>No</td></tr><tr><a name=d34928e449 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e450 class=n-a></a><b>Budapest<sup><a href="#ref-19">19</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e457 class=n-a></a>1995–1998</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e460 class=n-a></a>207 (NR)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e463 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e466 class=n-a></a>EBRT; HDR<br class=br>brachytherapy<a href="#TFN1">°</a><br class=br>WBI vs. WBI+boost</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e475 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e479 class=n-a></a>At 5 years:<br class=br>5.1% (WBI)<br class=br>vs. 7.3%<br class=br>(WBI+boost);<br class=br><i>P</i> = 0.049</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e492 class=n-a></a>No</td></tr><tr><a name=d34928e495 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e496 class=n-a></a><b>SWG<sup><a href="#ref-20">20</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e503 class=n-a></a>1996–NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e506 class=n-a></a>674 (NR)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e509 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e512 class=n-a></a>EBRT<a href="#TFN1">°</a> WBI vs.<br class=br>WBI+boost</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e520 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e524 class=n-a></a>At 8.5 years:<br class=br>2% (WBI) vs.<br class=br>4.4%<br class=br>(WBI+boost);<br class=br><i>P</i> = NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e537 class=n-a></a>No</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d34928e544 class=n-a></a><p id=d34928e546> EBRT, external beam radiotherapy; HDR, high-dose rate brachytherapy; LDR, low-dose-rate brachytherapy; LR, local relapse; NR, not reported; OS, overall survival; RT, radiotherapy; WBI, whole breast irradiation. </p><p id=TFN1>°Tumor bed boost techniques</p></div></div></div><p class="" id=d34928e556>Accelerated partial breast irradiation (APBI), combining increased dose per fraction, short duration of treatment, and small target volume confined to the tumor bed, represents an attractive de-escalating strategy in elderly women. The role of partial breast irradiation (PBI) has been investigated in large-scale prospective phase III clinical trials (<a href="#T2">Table 2</a>)<sup><a href="#ref-25">25</a>–<a href="#ref-29">29</a></sup>. The main recommendations published by the European Society for Radiotherapy and Oncology (ESTRO)<sup><a href="#ref-30">30</a></sup> and the American Society for Radiotherapy and Oncology (ASTRO)<sup><a href="#ref-31">31</a></sup> apply a specific age cut-off for defining patients who are suitable for PBI. Particularly, PBI is recommended only in patients older than 50. Regarding selected older patients (≥50 years, low tumor grade, up to 3 cm diameter, positive status of estrogen receptor, and HER2-negative status without nodal involvement), the 2016 UK consensus statements on breast cancer adjuvant irradiation recommended choosing external beam RT (EBRT) or multiple catheter brachytherapy PBI<sup><a href="#ref-32">32</a></sup>. Single fraction intra-operative RT (IORT) has been tested in two large phase III RCTs with conflicting results, making its recommendation for this subset of patients still controversial<sup><a href="#ref-28">28</a>,<a href="#ref-29">29</a></sup>.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Phase III trials investigating partial breast irradiation.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d34928e600 class=n-a></a><thead><a name=d34928e602 class=n-a></a><tr><a name=d34928e604 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e606 class=n-a></a>Trial</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e609 class=n-a></a>Study<br class=br>period</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e614 class=n-a></a>Study<br class=br>patients,<br class=br>overall<br class=br>(elderly)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e623 class=n-a></a>Elderly<br class=br>patients (%)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e628 class=n-a></a>RT technique, study<br class=br>design</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e634 class=n-a></a>OS rates</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e637 class=n-a></a>LR rates</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e640 class=n-a></a>Subgroup<br class=br>analysis<br class=br>in elderly</th></tr></thead><tbody><a name=d34928e649 class=n-a></a><tr><a name=d34928e651 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e652 class=n-a></a><b>IMRT APBI</b><br class=br><b>Florence<sup><a href="#ref-25">25</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e662 class=n-a></a>2005–2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e665 class=n-a></a>520 (117)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e668 class=n-a></a>22.5 (&gt;o = 70<br class=br>years) </td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e673 class=n-a></a>Accelerated IMRT<br class=br>APBI vs. WBI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e678 class=n-a></a>At 5-year: 99.4%<br class=br>(APBI) vs. 96.6%<br class=br>(WBI); <i>P</i> = 0.057</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e689 class=n-a></a>At 5-year: 1.5%<br class=br>(APBI) vs. 1.5%<br class=br>(WBI);<br class=br><i>P</i> = 0.86</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e700 class=n-a></a>Yes</td></tr><tr><a name=d34928e703 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e704 class=n-a></a><b>GEC-ESTRO<sup><a href="#ref-26">26</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e711 class=n-a></a>2004–2009</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e714 class=n-a></a>1,184 (190)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e717 class=n-a></a>16 (&gt;70 years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e720 class=n-a></a>Brachytherapy APBI<br class=br>vs. WBI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e725 class=n-a></a>At 5-year: 97.27%<br class=br>(APBI) vs. 95.55%<br class=br>(WBI);<br class=br><i>P</i> = 0.11</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e737 class=n-a></a>At 5-year: 1.44%<br class=br>(APBI) vs. 0.92%<br class=br>(WBI); <i>P</i> = 0.42</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e747 class=n-a></a>No</td></tr><tr><a name=d34928e750 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e751 class=n-a></a><b>IMPORT</b><br class=br><b>LOW<sup><a href="#ref-27">27</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e761 class=n-a></a>2007–2010</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e764 class=n-a></a>2,018 (NR)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e767 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e770 class=n-a></a>Normofractionated<br class=br>IMRT<br class=br>PBI vs. WBI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e777 class=n-a></a>At 5-year: 3.7%<br class=br>(PBI) vs. 5%<br class=br>(WBI);<br class=br><i>P</i> = 0.693</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e789 class=n-a></a>At 5-year: 0.5%<br class=br>(PBI) vs. 1.1%<br class=br>(WBI);<br class=br><i>P</i> = 0.420</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e800 class=n-a></a>No</td></tr><tr><a name=d34928e803 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e804 class=n-a></a><b>TARGIT-A<sup><a href="#ref-28">28</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e811 class=n-a></a>2000–2012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e814 class=n-a></a>3,451 (NR)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e817 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e820 class=n-a></a>IORT<a href="#TFN2">°</a><br class=br>IORT vs. WBI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e827 class=n-a></a>At 5-year: 96.1%<br class=br>(IORT) vs. 94.7%<br class=br>(WBI); <i>P</i> = 0.099</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e838 class=n-a></a>At 5-year: 3.3%<br class=br>(IORT) vs. 1.3%<br class=br>(WBI);<br class=br><i>P</i> = 0.042</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e849 class=n-a></a>No</td></tr><tr><a name=d34928e852 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e853 class=n-a></a><b>ELIOT<sup><a href="#ref-29">29</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e860 class=n-a></a>2000–2007</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e863 class=n-a></a>1,305 (137)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e866 class=n-a></a>10.5 (&gt;o = 70<br class=br>years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e871 class=n-a></a>IORT<a href="#TFN2">°</a> IORT vs. WBI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e877 class=n-a></a>At 5-year: 96.8%<br class=br>(IORT) vs. 96.9%<br class=br>(WBI); <i>P</i> = 0.59</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e888 class=n-a></a>At 5-year: 4.4%<br class=br>(IORT) vs. 0.4%<br class=br>(WBI);<br class=br><i>P</i> &lt;0.0001</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e899 class=n-a></a>Yes</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d34928e906 class=n-a></a><p id=d34928e908> APBI, accelerated partial breast irradiation; CI, confidence interval; EBRT, external beam radiotherapy; IBTR, ipsilateral breast tumor recurrence; IMRT, intensity modulated radiotherapy; IORT, intraoperative radiotherapy; LR, local relapse; NR, not reported; OS, overall survival; PBI, partial breast irradiation; RT, radiotherapy; WBI, whole breast irradiation.</p><p id=TFN2>°Experimental arm technique</p></div></div></div><p class="" id=d34928e917>IORT has several limitations, such as the lack of certain margin, the absence of image-guided treatment planning, and the use of low-energy photons. In order to minimize these aspects, Showalter <i>et al</i>. tested CT-based treatment planning and high-dose-rate (HDR) brachytherapy (CT-HDR-IORT). This novel technique permits 3D treatment planning, demonstrating a favorable feasibility and safety profile in women with early breast cancer. Currently, a phase II trial on CT-HDR-IORT is underway<sup><a href="#ref-33">33</a></sup>.</p><p class="" id=d34928e927>To date, only one dedicated paper has been published regarding the outcome of elderly patients undergoing PBI in a RCT. The authors’ subgroup analysis included elderly (≥70 years) women with early low-risk breast cancer (hormone receptor-positive, axillary node-negative, T1–T2 up to 3 cm, and clear margins). In this subpopulation, the reduction of overall treatment duration, consisting of a dose of 30 Gy in five non-consecutive daily fractions (2 weeks of treatment), led to a better quality of life profile and no significant difference in terms of IBTR compared with WBI<sup><a href="#ref-34">34</a></sup>.</p><p class="" id=d34928e934>In order to minimize the days of therapy schedules, many authors focused their efforts on different regimens of PBI, and several trials have been designed to evaluate novel HF APBI schedules<sup><a href="#ref-35">35</a>–<a href="#ref-40">40</a></sup>. Wilkinson <i>et al</i>.<sup><a href="#ref-35">35</a></sup> collected data from 45 patients undergoing adjuvant APBI in 2 days with HDR brachytherapy. The local, regional, and distant control were in line with literature, and toxicity was acceptable. In Latorre <i>et al</i>.’s analysis, considering a single 18 Gy fraction with multi-catheter HDR brachytherapy, none of the 20 patients reported grade three toxicity<sup><a href="#ref-36">36</a></sup>. According to Jethwa <i>et al</i>., the three-fraction once-daily intracavitary catheter-based partial breast brachytherapy (ICBB) presents a low rate of early provider and patient-reported adverse events and a favorable breast cosmesis at early follow-up<sup><a href="#ref-37">37</a></sup>. In addition, a three-fraction, phase II APBI trial (TRIUMPH: TRI-fraction Radiotherapy Utilized to Minimize Patient Hospital Trips) confirmed that ultrashort breast brachytherapy can be delivered with low toxicity and a good short-term tolerance profile<sup><a href="#ref-38">38</a></sup>. Compared with traditional 5-day treatment, these novel schedules of adjuvant RT have an excellent local control for early stage IBC and an acceptable toxicity profile, but they were not tested in elderly subpopulations and this patient group’s selection continues to be challenged. With this in mind, a retrospective analysis of elderly patients (≥65 years old) confirmed the excellent toxicity profile and clinical outcome of a postoperative single fraction of APBI<sup><a href="#ref-39">39</a></sup>. According to Hannoun-Lévi <i>et al</i>.’s data from 26 elderly patients treated with APBI (HDR brachytherapy), the clinical outcomes remain optimal and the toxicity profile was very low (with 15.4% and 3.9% of grade one and grade two toxicity, respectively)<sup><a href="#ref-40">40</a></sup>. In order to evaluate these two important endpoints and confirm these advantages in the elderly population, additional RCTs of HF APBI are needed.</p><p class="" id=d34928e981>In women aged 70 or older with low-risk, hormone-positive breast cancer, the literature and clinical practice focused efforts to escalate endocrine therapy (ET) and to de-escalate chemotherapy. However, the independent contribution of ET and chemotherapy on the quality of life is not clarified. Ferreira <i>et al</i>. reported that ET had a major detrimental effect on C30 summary score (C30-SumSc) at 2 years after diagnosis, especially in postmenopausal women. These results suggest that radiation therapy alone should be considered for older women with early stage, biologically favorable breast cancer<sup><a href="#ref-41">41</a>,<a href="#ref-42">42</a></sup>. Notably, Buszek <i>et al</i>. showed that for healthy, older women with biologically favorable disease, adjuvant irradiation or ET is related to similar 5-year overall survival (OS) rates. Thus, in order to evaluate monotherapy strategy, RCTs are needed<sup><a href="#ref-43">43</a>,<a href="#ref-44">44</a></sup>.</p><p class="" id=d34928e1005>Finally, the side effects of RT alone or when combined with other therapies are an important issue in elderly patients because of their impact on quality of life. To our knowledge, clinical guidelines recommend at least 5 years of treatment with adjuvant hormone therapy to prevent local relapse and improve survival<sup><a href="#ref-45">45</a></sup>. However, the toxicity profile of ET is relevant, specifically for the elderly, and ET adherence rates decline among women over 70<sup><a href="#ref-43">43</a>–<a href="#ref-46">46</a></sup>.</p><p class="" id=d34928e1019>On the other hand, adjuvant breast irradiation presents an excellent tolerance profile. The main side effects, skin reactions, edema, and fibrosis, do not significantly affect quality of life and patients’ daily activities. Moreover, radiation therapy adherence rates range from 98 to 99% and treatment period from 1 to 5 weeks, suggesting that it is potentially more suitable for the elderly population<sup><a href="#ref-47">47</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d34928e1029>Prostate cancer</h2><p class="" id=d34928e1032>The median age at prostate cancer (PC) diagnosis is 66 years, and 69% of deaths occur in men aged 75<sup><a href="#ref-48">48</a></sup>. Recent data suggest that significant comorbidity in elderly patients older than 75 should be a relative contraindication to aggressive treatment in low-risk PC<sup><a href="#ref-49">49</a></sup>; there are no published studies focused solely on the elderly. Current management decisions are based on life expectancy and geriatric assessment.</p><p class="" id=d34928e1043>Men with clinically localized PC, particularly with low-risk disease, have extremely low rates of cancer-specific mortality within 10 years of diagnosis. Among the feasible treatment strategies there are active surveillance (AS) and watchful waiting (WW). The distinction between these approaches is important for clinical decision-making. AS, which carries a curative intent and involves regular monitoring with prostate-specific antigen, digital rectal examination, and biopsy, is appropriate for patients who have sufficient life expectancy to benefit from active treatment if disease progression is detected. On the other hand, for patients with a life expectancy of less than 5 years, WW (cessation of routine monitoring with treatment initiated only if symptoms develop) is appropriate and further reduces the issue of overtreatment in PC<sup><a href="#ref-50">50</a></sup>.</p><p class="" id=d34928e1050>When RT is selected, androgen deprivation therapy (ADT) benefit is still unproven. In the RTOG 94-08 trial, 10-year survival in the low-risk group was similar after EBRT with or without ADT<sup><a href="#ref-51">51</a></sup>. In men with low-risk PC who decline AS and choose active treatment with EBRT, HF and extreme HF, consisting of fraction size ≥500 cGy (typically with a maximum number of five fractions), may be offered as an alternative to conventional fractionation. According to the current state of the art, there are no RCTs reporting efficacy and toxicity data on the comparison between ultra-HF and conventionally fractionated schedules. However, several prospective non-randomized studies have confirmed the safety of ultra-HF for localized PC patients; these findings seem to be applicable to patients without severe urinary symptoms and with up to 100 cm<sup>3</sup> of prostate volume at baseline. Currently, several trials are ongoing or in design (<a href="#T3">Table 3</a>)<sup><a href="#ref-52">52</a></sup>.</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Randomized trials evaluating ultra-hypofractionated external beam radiotherapy in prostate cancer.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d34928e1078 class=n-a></a><thead><a name=d34928e1080 class=n-a></a><tr><a name=d34928e1082 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1084 class=n-a></a>Trial</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1087 class=n-a></a>Planned<br class=br>accrual</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1092 class=n-a></a>Elderly<br class=br>patients<br class=br>(%)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1099 class=n-a></a>Cancer<br class=br>risk<br class=br>groups</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1106 class=n-a></a>Primary<br class=br>endpoint</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1112 class=n-a></a>Ultra-<br class=br>hypofractionated<br class=br>arm</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1119 class=n-a></a>Comparator<br class=br>arm</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1124 class=n-a></a>Status</th></tr></thead><tbody><a name=d34928e1129 class=n-a></a><tr><a name=d34928e1131 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1132 class=n-a></a><b>HEAT</b><br class=br><b>NCT01794403</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1139 class=n-a></a>456</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1142 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1145 class=n-a></a>LR and<br class=br>IR </td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1150 class=n-a></a>Biochemical<br class=br>or<br class=br>clinical failure</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1157 class=n-a></a>36.25 Gy in five<br class=br>fractions </td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1163 class=n-a></a>70.20 Gy in<br class=br>26 fractions </td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1168 class=n-a></a>Accruing</td></tr><tr><a name=d34928e1171 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1172 class=n-a></a><b>HYPO-RT-PC</b><br class=br><b>ISRCTN45905321</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1179 class=n-a></a>1,200</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1182 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1185 class=n-a></a>IR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1188 class=n-a></a>Biochemical<br class=br>or<br class=br>clinical failure</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1195 class=n-a></a>42.7 Gy in seven<br class=br>fractions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1201 class=n-a></a>78 Gy in 39<br class=br>fractions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1206 class=n-a></a>Accrual<br class=br>complete</td></tr><tr><a name=d34928e1211 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1212 class=n-a></a><b>NRG-GU005</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1216 class=n-a></a>606</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1219 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1222 class=n-a></a>IR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1225 class=n-a></a>Health-related<br class=br>quality of<br class=br>life toxicity<br class=br>assessment</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1234 class=n-a></a>36.25 Gy in five<br class=br>fractions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1240 class=n-a></a>70 Gy in 28<br class=br>fractions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1245 class=n-a></a>Accruing</td></tr><tr><a name=d34928e1248 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1249 class=n-a></a><b>PACE B</b><br class=br><b>NCT01584258</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1256 class=n-a></a>858</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1259 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1262 class=n-a></a>LR and<br class=br>IR </td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1267 class=n-a></a>Biochemical<br class=br>or<br class=br>clinical failure</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1274 class=n-a></a>36.25 Gy in five<br class=br>fractions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1280 class=n-a></a>78 Gy in 39<br class=br>fractions or<br class=br>62 Gy in 20<br class=br>fractions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1289 class=n-a></a>Accrual<br class=br>complete</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d34928e1298 class=n-a></a><p id=d34928e1300> IR, intermediate risk; LR, low risk; NR, not reported.</p></div></div></div><p class="" id=d34928e1307>In intermediate-risk patients, large randomized trials<sup><a href="#ref-51">51</a></sup> showed that the addition of hormones to EBRT resulted in increased survival<sup><a href="#ref-53">53</a>–<a href="#ref-55">55</a></sup>. Finally, in high-risk PC patients, combined therapy is the gold standard established by the Early Prostate Cancer Program and EORTC trials<sup><a href="#ref-56">56</a></sup>. Regarding the chance of reduction of treatment in the elderly, Bekelman et al. showed that in locally advanced PC patients (over 75 years of age), ADT with RT was associated with reduced cause-specific and all-cause mortality, and it remains the gold standard of therapy for PC patients of all ages<sup><a href="#ref-57">57</a></sup>.</p><p class="" id=d34928e1329>Concerning radiation treatment de-intensification in terms of overall treatment time, multiple phase III RCTs and meta-analyses have compared oncologic outcomes, toxicity, and quality of life for moderate HF versus conventional fractionation. Moderate HF has the advantage of shortening treatment duration and improving cost-effectiveness with a gain in terms of patient compliance, especially in the elderly population (<a href="#T4">Table 4</a>)<sup><a href="#ref-58">58</a>–<a href="#ref-64">64</a></sup>. In patients who are candidates for EBRT, the HF regimen should be offered with similar acute toxicity regardless of the patient’s class of risk, age, and comorbidities<sup><a href="#ref-52">52</a></sup>.</p><a name=T4 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 4. Randomized trials evaluating hypofractionated regimen.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d34928e1357 class=n-a></a><thead><a name=d34928e1359 class=n-a></a><tr><a name=d34928e1361 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1363 class=n-a></a>Trial</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1366 class=n-a></a>Study<br class=br>period</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1371 class=n-a></a>Study<br class=br>patients,<br class=br>overall<br class=br>(elderly)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1380 class=n-a></a>Elderly<br class=br>patients<br class=br>(%)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1387 class=n-a></a>Median<br class=br>FUP</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1393 class=n-a></a>Study design</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1396 class=n-a></a>Study arms</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1399 class=n-a></a>RT<br class=br>technique</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1404 class=n-a></a>Cancer<br class=br>risk<br class=br>groups</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1411 class=n-a></a>ADT use<br class=br>and<br class=br>duration<br class=br>(median)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1420 class=n-a></a>Age<br class=br>(median)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1426 class=n-a></a>Disease<br class=br>control<br class=br>(hazard<br class=br>ratio – 1<a href="#TFN4">°</a><br class=br>endpoint)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e1439 class=n-a></a>Subgroup<br class=br>analysis<br class=br>in elderly</th></tr></thead><tbody><a name=d34928e1448 class=n-a></a><tr><a name=d34928e1450 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1451 class=n-a></a><b>CHHiP<sup><a href="#ref-58">58</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1458 class=n-a></a>2002–2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1461 class=n-a></a>3,216<br class=br>(1,615)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1466 class=n-a></a>50.2<br class=br>(&gt;69<br class=br>years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1473 class=n-a></a>5.2<br class=br>years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1478 class=n-a></a>Multicenter non-<br class=br>inferiority<br class=br>trial<br class=br>1<a href="#TFN4">°</a> endpoint:<br class=br>biochemical or<br class=br>clinical failure-free<br class=br>rate</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1498 class=n-a></a>74 Gy in 37<br class=br>fractions<br class=br>60 Gy in 20<br class=br>fractions<br class=br>57 Gy in 19<br class=br>fractions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1511 class=n-a></a>IMRT<br class=br>IGRT<br class=br>optional<br class=br>(53% use)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1520 class=n-a></a>12% HR<br class=br>15% LR<br class=br>73% IR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1527 class=n-a></a>97%<br class=br>3–6 months<br class=br>(median<br class=br>5.5 months)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1536 class=n-a></a>68 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1539 class=n-a></a>60 vs. 74<br class=br>Gy: 0.83<br class=br>(90% CI:<br class=br>0.64–1.14)<br class=br>57 vs. 74<br class=br>Gy: 1.20<br class=br>(90% CI:<br class=br>0.99–1.46)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1558 class=n-a></a>Yes</td></tr><tr><a name=d34928e1561 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1562 class=n-a></a><b>HYPRO<sup><a href="#ref-59">59</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1569 class=n-a></a>2007–2010</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1572 class=n-a></a>820 (411)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1575 class=n-a></a>50.1<br class=br>(&gt;70<br class=br>years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1582 class=n-a></a>5 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1585 class=n-a></a>Multicenter<br class=br>superiority<br class=br>1<a href="#TFN4">°</a> endpoint:<br class=br>relapse-free<br class=br>survival</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1600 class=n-a></a>78 Gy in 39<br class=br>fractions<br class=br>64.6 Gy in 19<br class=br>fractions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1609 class=n-a></a>IMRT<br class=br>IGRT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1614 class=n-a></a>26%<br class=br>IR 74%<br class=br>HR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1621 class=n-a></a>67%<br class=br>Variable<br class=br>duration<br class=br>(median<br class=br>32.4<br class=br>months)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1634 class=n-a></a>71 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1637 class=n-a></a>0.86<br class=br>(95% CI:<br class=br>0.63–1.16)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1645 class=n-a></a>Yes</td></tr><tr><a name=d34928e1648 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1649 class=n-a></a><b>PROFIT<sup><a href="#ref-60">60</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1656 class=n-a></a>2006–2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1659 class=n-a></a>1,206<br class=br>(NR)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1664 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1667 class=n-a></a>6 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1670 class=n-a></a>Multicenter non-<br class=br>inferiority trial<br class=br>1<a href="#TFN4">°</a> endpoint:<br class=br>biochemical or<br class=br>clinical failure</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1685 class=n-a></a>78 Gy in 39<br class=br>fractions 60 Gy<br class=br>in 20 fractions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1692 class=n-a></a>IMRT or<br class=br>3D CRT<br class=br>IGRT<br class=br>required</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1701 class=n-a></a>100% IR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1704 class=n-a></a>None</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1707 class=n-a></a>71 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1710 class=n-a></a>0.99<br class=br>(90% CI:<br class=br>0.83–1.19)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1718 class=n-a></a>No</td></tr><tr><a name=d34928e1721 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1722 class=n-a></a><b>RTOG</b><br class=br><b>0415<sup><a href="#ref-61">61</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1732 class=n-a></a>2006–2009</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1735 class=n-a></a>1,115<br class=br>(420)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1740 class=n-a></a>37.7<br class=br>(&gt; o =70<br class=br>years) </td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1747 class=n-a></a>5.8<br class=br>years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1752 class=n-a></a>Multicenter non-<br class=br>inferiority trial<br class=br>1<a href="#TFN4">°</a> endpoint:<br class=br>disease-free<br class=br>survival</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1767 class=n-a></a>73.8 Gy in 41<br class=br>fractions<br class=br>70 Gy in 28<br class=br>fractions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1776 class=n-a></a>IMRT or<br class=br>3D CRT<br class=br>IGRT<br class=br>required</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1785 class=n-a></a>100% LR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1788 class=n-a></a>None</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1791 class=n-a></a>67 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1794 class=n-a></a>0.85<br class=br>(95% CI:<br class=br>0.64–1.14)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1802 class=n-a></a>No</td></tr><tr><a name=d34928e1805 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1806 class=n-a></a><b>Fox</b><br class=br><br class=br><b>Chase<sup><a href="#ref-62">62</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1817 class=n-a></a>2002–2006</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1820 class=n-a></a>303 (NR)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1823 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1826 class=n-a></a>5.7<br class=br>years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1831 class=n-a></a>Single institution<br class=br>superiority trial<br class=br>1<a href="#TFN4">°</a> endpoint:<br class=br>biochemical<br class=br>disease-free<br class=br>survival</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1849 class=n-a></a>76 Gy in 38<br class=br>fractions<br class=br>70.2 Gy in 26<br class=br>fractions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1858 class=n-a></a>IMRT u/s<br class=br>IGRT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1863 class=n-a></a>66%<br class=br>IR 33%<br class=br>HR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1870 class=n-a></a>46%<br class=br>(median<br class=br>NR)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1877 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1880 class=n-a></a>1.38<br class=br>(95% CI:<br class=br>0.79–2.40)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1888 class=n-a></a>No</td></tr><tr><a name=d34928e1892 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1893 class=n-a></a><b>MD</b><br class=br><b>Anderson<sup><a href="#ref-63">63</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1903 class=n-a></a>2001–2010</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1906 class=n-a></a>206 (82)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1909 class=n-a></a>39.8<br class=br>(&gt; o =70<br class=br>years) </td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1916 class=n-a></a>5 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1919 class=n-a></a>Single institution<br class=br>superiority trial 1<a href="#TFN4">°</a><br class=br>endpoint: failure-<br class=br>free survival</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1931 class=n-a></a>75.6 Gy in 42<br class=br>fractions<br class=br>72 Gy in 30<br class=br>fractions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1940 class=n-a></a>IMRT or<br class=br>IGRT </td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1945 class=n-a></a>28% LR<br class=br>71% IR<br class=br>1% HR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1952 class=n-a></a>24%<br class=br>&lt;4 months<br class=br>(median<br class=br>not<br class=br>reported) </td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1963 class=n-a></a>67 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1966 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1970 class=n-a></a>No</td></tr><tr><a name=d34928e1973 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1974 class=n-a></a><b>Italian<sup><a href="#ref-64">64</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1981 class=n-a></a>2003–2007</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1984 class=n-a></a>168 (NR)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1987 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1990 class=n-a></a>9 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e1993 class=n-a></a>Single institution<br class=br>superiority trial<br class=br>1<a href="#TFN4">°</a> endpoint: late<br class=br>toxicity</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2006 class=n-a></a>80 Gy in 40<br class=br>fractions<br class=br>62 Gy in 20<br class=br>fractions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2015 class=n-a></a>3D CRT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2018 class=n-a></a>100% HR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2021 class=n-a></a>100%<br class=br>9 months<br class=br>(median<br class=br>NR)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2030 class=n-a></a>75 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2033 class=n-a></a>0.62<br class=br>(95% CI:<br class=br>0.34-1.14)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2041 class=n-a></a>Yes</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d34928e2048 class=n-a></a><p id=TFN4> 1°, primary; ADT, androgen deprivation therapy; CI, confidence interval; CRT, conformal radiation therapy; EBRT, external beam radiotherapy; FUP, follow up; HR, high risk; IGRT, image-guided radiation therapy; IMRT, intensity modulated radiotherapy; IR, intermediate risk; LR, low risk; NR, not reported; RT, radiotherapy.</p></div></div></div><p class="" id=d34928e2056>A SIOG PC task force has updated recommendations for the management of elderly men with PC showing that these patients should be managed according to their health status and not according to age, although the extrapolation specifically to older patients is not straightforward. For these reasons, new clinical trials targeting the elderly population are needed<sup><a href="#ref-65">65</a></sup>.</p><p class="" id=d34928e2063>Finally, radiation treatment for localized PC is associated with potential side effects, particularly in the elderly population. In EBRT, acute adverse events are typically not severe and resolve within 4–8 weeks after treatment; regarding long-term side effects, proctitis with bloody stools are the most common late rectal toxicities<sup><a href="#ref-66">66</a></sup>. Compared with radical prostatectomy, aside from a worse performance when considering quality of life in the bowel domain, RT is associated with better quality of life regarding urinary and sexual disorders<sup><a href="#ref-67">67</a></sup>. In addition, patients undergoing pelvic RT present an increased risk for fractures, spontaneously or after minimal trauma. In light of this, Vitztum <i>et al</i>. evaluated 28,354 patients aged over 65 undergoing RT for pelvic malignancies and found that IMRT and brachytherapy were associated with a reduced risk of pelvic fractures. Pelvic insufficiency fracture risk should be considered when treating old PC patients with radiation treatments<sup><a href="#ref-68">68</a></sup>. On the other hand, the use of ADT is not without adverse events. A recent analysis of 31 patients highlighted the high prevalence of muscle disorders, such as sarcopenia, before the initiation of ADT in a population of elderly PC patients<sup><a href="#ref-69">69</a></sup>. The optimal strategy for the elderly should be based on all of the aforementioned issues, but the correct patient selection continues to be challenged and additional studies in this subpopulation are needed.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d34928e2088>Lung cancer</h2><p class="" id=d34928e2091>Elderly cancer patients are significantly under-represented in all clinical trials, including lung cancer studies. ASTRO recommends a management strategy involving multiple disciplines and patients and physicians sharing the decision-making in early stage non-small cell lung cancer (NSCLC). Current recommendations include the use of stereotactic body RT (SBRT) in patients considered to be high risk for surgery, including those with either forced expiratory volume at 1 second or diffusing capacity of the lungs for carbon monoxide less than 50% predicted or a combination of age, reduced lung function, pulmonary hypertension, and low left ventricular function<sup><a href="#ref-70">70</a></sup>.</p><p class="" id=d34928e2098>Insights regarding the utilization and survival of surgery and SBRT or conventional RT are lacking for older patients with stage I and II NSCLC in clinical practice. Because of limited accrual, a number of randomized trials evaluating surgery compared to SBRT in early stage operable patients have closed early. Nevertheless, a recent pooled analysis, based on STARS and ROSEL trials, did point out comparable local control and OS rates between surgery and SBRT. This approach represents a feasible, non-invasive treatment strategy for elderly patients with early stage NSCLC (<a href="#T5">Table 5</a>)<sup><a href="#ref-71">71</a></sup>. There are several retrospective studies examining outcomes between SBRT and surgery in older adult patients with early stage NSCLC (<a href="#T6">Table 6</a>)<sup><a href="#ref-72">72</a></sup>. Miyazaki <i>et al.</i> evaluated 98 patients with early stage NSCLC who were 80 years of age or older and who underwent SBRT or resection. Toxicities were similar and, after propensity score matching allowed for balanced patient characteristics, there were no significant differences in 5-year OS or disease-specific survival between the two treatments<sup><a href="#ref-73">73</a></sup>. Wang <i>et al.</i> performed a similar study and patients undergoing surgery were younger than populations undergoing SBRT (median age 72 versus 82), were in better health, and had better Eastern Cooperative Oncology Group (ECOG) performance status scores. According to propensity-score matching, surgery, compared to SBRT, still showed better locoregional relapse and recurrence-free survival with no significant results in terms of OS and disease-specific survival in this subset<sup><a href="#ref-74">74</a></sup>. Palma <i>et al.</i> evaluated patients 75 years of age or older with early stage NSCLC between 2005 and 2007. Comparison between 60 patients undergoing SBRT and 60 patients treated with surgery showed that 1- and 3-year OS rates were not significantly different and that 30-day mortality was 8.3% and 1.7% for surgery and SBRT, respectively<sup><a href="#ref-75">75</a></sup>. All of these retrospective studies suggest SBRT may be a feasible and effective treatment modality in comparison to surgical resection despite the fact that further prospective data are needed, specifically in elderly patients.</p><a name=T5 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 5. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: two randomized trials.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d34928e2148 class=n-a></a><thead><a name=d34928e2150 class=n-a></a><tr><a name=d34928e2152 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2154 class=n-a></a>Trial</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2157 class=n-a></a>Study<br class=br>period</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2162 class=n-a></a>Study<br class=br>patients,<br class=br>overall<br class=br>(elderly)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2171 class=n-a></a>Elderly<br class=br>patients<br class=br>(%)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2178 class=n-a></a>RT technique,<br class=br>study design</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2184 class=n-a></a>OS rates</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2187 class=n-a></a>LR rates</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2190 class=n-a></a>Subgroup<br class=br>analysis<br class=br>in elderly</th></tr></thead><tbody><a name=d34928e2199 class=n-a></a><tr><a name=d34928e2201 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2203 class=n-a></a><b>STARS and</b><br class=br><b>ROSEL trials</b><br class=br><b><sup><a href="#ref-71">71</a></sup></b><br class=br><b>[STARS:</b><br class=br><b>NCT00840749;</b><br class=br><b>ROSEL:</b><br class=br><b>NCT00687986]</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2228 class=n-a></a>2008–2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2231 class=n-a></a>STARS:<br class=br>36 (NR);<br class=br>ROSEL:<br class=br>22 (NR)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2240 class=n-a></a>STARS:<br class=br>NR<br class=br>ROSEL:<br class=br>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2249 class=n-a></a>STARS<br class=br>CyberKnife SABR<br class=br>60 Gy in four<br class=br>fractions or 60 Gy<br class=br>in three fractions<br class=br>vs. surgery<br class=br>(thoracotomy and<br class=br>VATS)<br class=br>ROSEL<br class=br>SABR 54 Gy in<br class=br>three fractions<br class=br>or 60 Gy in five<br class=br>fractions vs.<br class=br>surgery</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2281 class=n-a></a>3-year OS (95%<br class=br>CI):<br class=br>SABR 95%<br class=br>(85–100); surgery<br class=br>79% (64–97)<br class=br>HR (95% CI): 0.14<br class=br>(0.017–1.190)<br class=br><i>P</i> = 0.037</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2301 class=n-a></a>3-year RFS (95% CI):<br class=br>SABR 86% (74–100);<br class=br>surgery 80% (65–97)<br class=br>HR (95% CI): 0.69<br class=br>(0.21–2.29) <i>P</i> = 0.5379</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2315 class=n-a></a>No</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d34928e2323 class=n-a></a><p id=d34928e2325> CI, confidence interval; HR, hazard ratio; LR, local recurrence; NR, not reported; OS, overall survival; RFS, recurrence-free survival; SABR, stereotactic ablative radiotherapy; RT, radiotherapy; VATS, video-assisted thoracotomy.</p></div></div></div><a name=T6 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 6. Retrospective studies examining outcomes between stereotactic body radiotherapy and surgery in older adult patients with early stage non-small cell lung cancer.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d34928e2342 class=n-a></a><thead><a name=d34928e2344 class=n-a></a><tr><a name=d34928e2346 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2348 class=n-a></a>Trial</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2351 class=n-a></a>Study<br class=br>period</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2356 class=n-a></a>Study<br class=br>patients,<br class=br>overall<br class=br>(elderly)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2365 class=n-a></a>Elderly<br class=br>patients<br class=br>(%)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2372 class=n-a></a>RT technique, study design</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2376 class=n-a></a>OS rates</th><th align=left colspan=1 rowspan=1 valign=top><a name=d34928e2379 class=n-a></a>LR</th></tr></thead><tbody><a name=d34928e2384 class=n-a></a><tr><a name=d34928e2386 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2388 class=n-a></a><b>Miyazaki <i>et al</i>.<sup><a href="#ref-73">73</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2398 class=n-a></a>2008–2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2401 class=n-a></a>98 (98)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2404 class=n-a></a>100 (&gt;80<br class=br>years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2409 class=n-a></a>SBRT (48 Gy in four fractions) vs.<br class=br>surgery (lobectomy)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2415 class=n-a></a>5-year OS with SBRT<br class=br>68.3% (n = 57) vs.<br class=br>47.4% (n = 41),<br class=br>HR=2.46 (95% CI<br class=br>1.18–5.48), <i>P</i> = 0.02</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2429 class=n-a></a>NR</td></tr><tr><a name=d34928e2433 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2435 class=n-a></a><b>Wang <i>et al</i>.<sup><a href="#ref-74">74</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2445 class=n-a></a>2002–2010</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2448 class=n-a></a>180 (100)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2451 class=n-a></a>55.5 (&gt;75<br class=br>years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2456 class=n-a></a>SBRT (60 Gy in five fractions)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2460 class=n-a></a>3-year OS with SBRT<br class=br>54.9%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2465 class=n-a></a>3-year LRC<br class=br>with SBRT:<br class=br>68.8%</td></tr><tr><a name=d34928e2473 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2475 class=n-a></a><b>Palma <i>et al</i>.<sup><a href="#ref-75">75</a></sup></b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2485 class=n-a></a>2005–2007</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2488 class=n-a></a>346 (346)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d34928e2491 class=n-a></a>100 (&gt;o =<br class=br>75 years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2496 class=n-a></a>SBRT (60 in three, five, or eight<br class=br>fractions) vs. surgery (lobectomy,<br class=br>pneumonectomy or sublobar<br class=br>excision)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2506 class=n-a></a>3-year OS with SBRT<br class=br>42%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d34928e2511 class=n-a></a>NR</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d34928e2518 class=n-a></a><p id=d34928e2520> CI, confidence interval; HR, hazard ratio; LC, local control; LR, local recurrence; LRC, locoregional control; NR, not reported; OS, overall survival; RT, radiotherapy; SBRT, stereotactic body radiotherapy.</p></div></div></div><p class="" id=d34928e2527>According to current standards, local treatment, such as SBRT, is not reasonable for more advanced NSCLC; combined RT to the primary and involved nodes with chemotherapy tailored to comorbidities is the correct treatment modality in selected inoperable patients. In older patients undergoing surgical resection, efforts should focus on selecting an appropriate postoperative treatment for positive margins or pN2 disease<sup><a href="#ref-76">76</a></sup>.</p><p class="" id=d34928e2534>Typically, RT has been associated with chemotherapy to improve outcome; with the introduction of immune checkpoint inhibitors as an effective treatment strategy, the evaluation of outcomes of concomitant RT and immunotherapy becomes mandatory<sup><a href="#ref-77">77</a></sup>. A lot of retrospective studies reported that radiation treatment has the potential to enhance the effects of checkpoint inhibition in selected patients. Similarly, some preclinical studies described a synergic effect of combination radiation–immunotherapy<sup><a href="#ref-78">78</a></sup>. Currently, numerous RCTs testing the combination of immunotherapy and radiation are ongoing<sup><a href="#ref-79">79</a>,<a href="#ref-80">80</a></sup>. Data from the PACIFIC trial, a phase III randomized study, evaluated consolidation therapy after chemoradiation for stage III NSCLC with the anti-PDL1 durvalumab versus placebo. The results confirmed the benefit of durvalumab in progression-free survival (PFS) while preserving a similar toxicity profile<sup><a href="#ref-81">81</a></sup>.</p><p class="" id=d34928e2556>Regarding limited-disease small-cell lung cancer (LD-SCLC), phase III trials, in which older patients were as usual excluded, show that the standard treatment strategy remains platinum-based multiagent chemotherapy and thoracic and cranial irradiation<sup><a href="#ref-82">82</a></sup>. De-intensification of treatment in this setting of elderly patients has been investigated through diminutions in time and intensity of both treatments with heterogeneous findings, and standard chemoradiation is still suitable for fit older patients. The comparison between conventional (66 Gy) and accelerated (45 Gy b.i.d.) fractionation with standard platinum-based chemotherapy (cisplatin/etoposide) in patients of all ages (the phase-III CONVERT trial) highlights that survival outcomes did not differ between twice-daily and once-daily concurrent chemoradiotherapy, with a similar toxicity profile. Since the study was not powered to confirm equivalence between different treatment protocols, the conclusion is that twice-daily irradiation remains the standard therapy in this population<sup><a href="#ref-83">83</a>,<a href="#ref-84">84</a></sup>.</p><p class="" id=d34928e2570>For both locoregionally advanced NSCLC and LD-SCLC, the investigation of concomitant treatment strategies incorporating newer chemotherapy and targeted agents, potentially less toxic than current cisplatin-based therapy, is warranted, especially in elderly patients.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d34928e2576>Conclusion</h2><p class="" id=d34928e2579>The evidence discussed herein emphasizes the need to more thoroughly research the elderly patient population, a group that is frequently overlooked in treatment guidelines. The complex heterogeneity of this patient group, in terms of age, comorbidities, and the presence of a caregiver, may warrant the historical exclusion of older patients from randomized trials. CGA and other surrogates such as G8 have not been fully implemented both in academic and in everyday practice. Lastly, the inclusion of older patients in clinical studies should be strongly encouraged to strengthen the evidence base for this age group. In this regard, we recommend a multidisciplinary approach based on the collaboration among surgeons, radiation oncologists, medical oncologists, and geriatricians. The creation of oncogeriatric coordination units may promote individualized care protocols, avoid overtreatment with aggressive and unrecommended therapies, and support de-escalating treatment in elderly cancer patients.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d34928e2586>Abbreviations</h2><p class="" id=d34928e2589>ADT, androgen deprivation therapy; APBI, accelerated partial breast irradiation; AS, active surveillance; ASTRO, American Society for Radiotherapy; BCS, breast-conserving surgery; CGA, comprehensive geriatric assessment; CT, computed tomography; EBRT, external beam radiation therapy; ET, endocrine therapy; HDR, high dose rate; HF, hypofractionation; IBC, invasive breast cancer; IBTR, ipsilateral breast tumor recurrence; IMRT, intensity-modulated radiation therapy; IORT, intra-operative radiotherapy; LD-SCLC, limited-disease small-cell lung cancer; NSCLC, non-small cell lung cancer; OS, overall survival; PBI, partial breast irradiation; PC, prostate cancer; RCT, randomized controlled trial; RT, radiotherapy; SBRT, stereotactic body radiotherapy; WBI, whole breast irradiation; WW, watchful waiting. </p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d34928e2596 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d35485>References</h2><div class="section ref-list"><a name=d34928e2596 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735359650"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e2603 class=n-a></a>Popescu T, Karlsson U, Vinh-Hung V, <i> et al.</i>: Challenges Facing Radiation Oncologists in The Management of Older Cancer Patients: Consensus of The International Geriatric Radiotherapy Group. <i>Cancers (Basel).</i> 2019; <b>11</b>(3): pii: E371. <a target=xrefwindow id=d34928e2614 href="http://www.ncbi.nlm.nih.gov/pubmed/30884827">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2617 href="https://doi.org/10.3390/cancers11030371">Publisher Full Text </a> | <a target=xrefwindow id=d34928e2621 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6468336">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735359650">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d34928e2634 class=n-a></a>Shrivastava SR, Shrivastava PS, Ramasamy J: Health-care of Elderly: Determinants, Needs and Services. <i>Int J Prev Med.</i> 2013; <b>4</b>(10): 1224–5. <a target=xrefwindow id=d34928e2642 href="http://www.ncbi.nlm.nih.gov/pubmed/24319566">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2645 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3843313">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d34928e2654 class=n-a></a>Decoster L, van Puyvelde K, Mohile S, <i> et al.</i>: Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. <i>Ann Oncol.</i> 2015; <b>26</b>(2): 288–300. <a target=xrefwindow id=d34928e2665 href="http://www.ncbi.nlm.nih.gov/pubmed/24936581">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2668 href="https://doi.org/10.1093/annonc/mdu210">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d34928e2677 class=n-a></a>Soubeyran P, Bellera C, Goyard J, <i> et al.</i>: Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. <i>PLoS One.</i> 2014; <b>9</b>(12): e115060. <a target=xrefwindow id=d34928e2688 href="http://www.ncbi.nlm.nih.gov/pubmed/25503576">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2691 href="https://doi.org/10.1371/journal.pone.0115060">Publisher Full Text </a> | <a target=xrefwindow id=d34928e2695 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4263738">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727833580"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e2704 class=n-a></a>Pfeffer MR, Blumenfeld P: The Changing Paradigm of Radiotherapy in the Elderly Population. <i>Cancer J.</i> 2017; <b>23</b>(4): 223–30. <a target=xrefwindow id=d34928e2712 href="http://www.ncbi.nlm.nih.gov/pubmed/28731945">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2715 href="https://doi.org/10.1097/PPO.0000000000000271">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727833580">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718310784"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e2729 class=n-a></a>Kunkler IH, Audisio R, Belkacemi Y, <i> et al.</i>: Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. <i>Ann Oncol.</i> 2014; <b>25</b>(11): 2134–46. <a target=xrefwindow id=d34928e2740 href="http://www.ncbi.nlm.nih.gov/pubmed/24625455">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2743 href="https://doi.org/10.1093/annonc/mdu104">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718310784">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d34928e2756 class=n-a></a>Ten Haken RK, Lawrence TS: The clinical application of intensity-modulated radiation therapy. <i>Semin Radiat Oncol.</i> 2006; <b>16</b>(4): 224–31. <a target=xrefwindow id=d34928e2764 href="http://www.ncbi.nlm.nih.gov/pubmed/17010905">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2767 href="https://doi.org/10.1016/j.semradonc.2006.04.005">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d34928e2776 class=n-a></a>Wu VW, Law MY, Star-Lack J, <i> et al.</i>: Technologies of image guidance and the development of advanced linear accelerator systems for radiotherapy. <i>Front Radiat Ther Oncol.</i> 2011; <b>43</b>: 132–64. <a target=xrefwindow id=d34928e2787 href="http://www.ncbi.nlm.nih.gov/pubmed/21625152">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2790 href="https://doi.org/10.1159/000322414">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d34928e2799 class=n-a></a>Swaminath A, Dawson LA: Emerging role of radiotherapy in the management of liver metastases. <i>Cancer J.</i> 2010; <b>16</b>(2): 150–5. <a target=xrefwindow id=d34928e2807 href="http://www.ncbi.nlm.nih.gov/pubmed/20404612">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2810 href="https://doi.org/10.1097/PPO.0b013e3181d7e8b3">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d34928e2819 class=n-a></a>Giugliano FM, Falivene S, Esposito E, <i> et al.</i>: External radiotherapy for breast cancer in the elderly. <i>Aging Clin Exp Res.</i> 2017; <b>29</b>(Suppl 1): 149–57. <a target=xrefwindow id=d34928e2830 href="http://www.ncbi.nlm.nih.gov/pubmed/27837457">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2833 href="https://doi.org/10.1007/s40520-016-0655-x">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718493924"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e2842 class=n-a></a>Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, <i> et al.</i>: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. <i>Lancet.</i> 2011; <b>378</b>(9804): 1707–16. <a target=xrefwindow id=d34928e2853 href="http://www.ncbi.nlm.nih.gov/pubmed/22019144">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2856 href="https://doi.org/10.1016/S0140-6736(11)61629-2">Publisher Full Text </a> | <a target=xrefwindow id=d34928e2860 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3254252">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718493924">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d34928e2874 class=n-a></a>Hughes KS, Schnaper LA, Bellon JR, <i> et al.</i>: Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. <i>J Clin Oncol.</i> 2013; <b>31</b>(19): 2382–7. <a target=xrefwindow id=d34928e2885 href="http://www.ncbi.nlm.nih.gov/pubmed/23690420">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2888 href="https://doi.org/10.1200/JCO.2012.45.2615">Publisher Full Text </a> | <a target=xrefwindow id=d34928e2892 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3691356">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d34928e2901 class=n-a></a>START Trialists' Group, Bentzen SM, Agrawal RK, <i> et al.</i>: The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. <i>Lancet.</i> 2008; <b>371</b>(9618): 1098–107. <a target=xrefwindow id=d34928e2912 href="http://www.ncbi.nlm.nih.gov/pubmed/18355913">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2915 href="https://doi.org/10.1016/S0140-6736(08)60348-7">Publisher Full Text </a> | <a target=xrefwindow id=d34928e2919 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2277488">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d34928e2928 class=n-a></a>Haviland JS, Agrawal R, Aird E, <i> et al.</i>: The UK START (Standardisation of Breast Radiotherapy) trials: 10-year follow-up results. <i>Cancer Res.</i> 2012; <b>72</b>: S3. </span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734025274"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e2946 class=n-a></a>Smith BD, Bellon JR, Blitzblau R, <i> et al.</i>: Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. <i>Pract Radiat Oncol.</i> 2018; <b>8</b>(3): 145–52. <a target=xrefwindow id=d34928e2957 href="http://www.ncbi.nlm.nih.gov/pubmed/29545124">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2960 href="https://doi.org/10.1016/j.prro.2018.01.012">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734025274">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d34928e2973 class=n-a></a>Bartelink H, Horiot JC, Poortmans PM, <i> et al.</i>: Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. <i>J Clin Oncol.</i> 2007; <b>25</b>(22): 3259–65. <a target=xrefwindow id=d34928e2984 href="http://www.ncbi.nlm.nih.gov/pubmed/17577015">PubMed Abstract </a> | <a target=xrefwindow id=d34928e2987 href="https://doi.org/10.1200/JCO.2007.11.4991">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/3970957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e2996 class=n-a></a>Vaidya JS, Joseph DJ, Tobias JS, <i> et al.</i>: Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. <i>Lancet.</i> 2010; <b>376</b>(9735): 91–102. <a target=xrefwindow id=d34928e3007 href="http://www.ncbi.nlm.nih.gov/pubmed/20570343">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3010 href="https://doi.org/10.1016/S0140-6736(10)60837-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/3970957">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d34928e3024 class=n-a></a>Romestaing P, Lehingue Y, Carrie C, <i> et al.</i>: Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. <i>J Clin Oncol.</i> 1997; <b>15</b>(3): 963–8. <a target=xrefwindow id=d34928e3035 href="http://www.ncbi.nlm.nih.gov/pubmed/9060534">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3038 href="https://doi.org/10.1200/JCO.1997.15.3.963">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d34928e3047 class=n-a></a>Polgár C, Fodor J, Orosz Z, <i> et al.</i>: Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer first results of the randomized Budapest boost trial. <i>Strahlenther Onkol.</i> 2002; <b>178</b>(11): 615–23. <a target=xrefwindow id=d34928e3058 href="http://www.ncbi.nlm.nih.gov/pubmed/12426672">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3061 href="https://doi.org/10.1007/s00066-002-1053-1">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d34928e3070 class=n-a></a>Hau E, Browne LH, Khanna S, <i> et al.</i>: Radiotherapy breast boost with reduced whole-breast dose is associated with improved cosmesis: the results of a comprehensive assessment from the St. George and Wollongong randomized breast boost trial. <i>Int J Radiat Oncol Biol Phys.</i> 2012; <b>82</b>(2): 682–9. <a target=xrefwindow id=d34928e3081 href="http://www.ncbi.nlm.nih.gov/pubmed/21255943">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3084 href="https://doi.org/10.1016/j.ijrobp.2010.11.025">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d34928e3093 class=n-a></a>Bartelink H, Maingon P, Poortmans P, <i> et al.</i>: Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(1): 47–56. <a target=xrefwindow id=d34928e3104 href="http://www.ncbi.nlm.nih.gov/pubmed/25500422">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3107 href="https://doi.org/10.1016/S1470-2045(14)71156-8">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d34928e3116 class=n-a></a>Kindts I, Laenen A, Depuydt T, <i> et al.</i>: Tumour bed boost radiotherapy for women after breast-conserving surgery. <i>Cochrane Database Syst Rev.</i> 2017; <b>11</b>: CD011987. <a target=xrefwindow id=d34928e3127 href="http://www.ncbi.nlm.nih.gov/pubmed/29105051">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3130 href="https://doi.org/10.1002/14651858.CD011987.pub2">Publisher Full Text </a> | <a target=xrefwindow id=d34928e3134 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6486034">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d34928e3143 class=n-a></a>Collette S, Collette L, Budiharto T, <i> et al.</i>: Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. <i>Eur J Cancer.</i> 2008; <b>44</b>(17): 2587–99. <a target=xrefwindow id=d34928e3154 href="http://www.ncbi.nlm.nih.gov/pubmed/18757193">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3157 href="https://doi.org/10.1016/j.ejca.2008.07.032">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d34928e3167 class=n-a></a>Vrieling C, Collette L, Fourquet A, <i> et al.</i>: The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. <i>Radiother Oncol.</i> 2000; <b>55</b>(3): 219–32. <a target=xrefwindow id=d34928e3178 href="http://www.ncbi.nlm.nih.gov/pubmed/10869738">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3181 href="https://doi.org/10.1016/s0167-8140(00)00210-3">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d34928e3190 class=n-a></a>Livi L, Meattini I, Marrazzo L, <i> et al.</i>: Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. <i>Eur J Cancer.</i> 2015; <b>51</b>(4): 451–63. <a target=xrefwindow id=d34928e3201 href="http://www.ncbi.nlm.nih.gov/pubmed/25605582">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3204 href="https://doi.org/10.1016/j.ejca.2014.12.013">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d34928e3213 class=n-a></a>Strnad V, Ott OJ, Hildebrandt G, <i> et al.</i>: 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. <i>Lancet.</i> 2016; <b>387</b>(10015): 229–38. <a target=xrefwindow id=d34928e3224 href="http://www.ncbi.nlm.nih.gov/pubmed/26494415">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3227 href="https://doi.org/10.1016/S0140-6736(15)00471-7">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727879066"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3236 class=n-a></a>Coles CE, Griffin CL, Kirby AM, <i> et al.</i>: Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. <i>Lancet.</i> 2017; <b>390</b>(10099): 1048–60. <a target=xrefwindow id=d34928e3247 href="http://www.ncbi.nlm.nih.gov/pubmed/28779963">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3250 href="https://doi.org/10.1016/S0140-6736(17)31145-5">Publisher Full Text </a> | <a target=xrefwindow id=d34928e3254 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5594247">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727879066">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718175577"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3267 class=n-a></a>Vaidya JS, Wenz F, Bulsara M, <i> et al.</i>: Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. <i>Lancet.</i> 2014; <b>383</b>(9917): 603–13. <a target=xrefwindow id=d34928e3278 href="http://www.ncbi.nlm.nih.gov/pubmed/24224997">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3281 href="https://doi.org/10.1016/S0140-6736(13)61950-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718175577">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d34928e3294 class=n-a></a>Veronesi U, Orecchia R, Maisonneuve P, <i> et al.</i>: Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. <i>Lancet Oncol.</i> 2013; <b>14</b>(13): 1269–77. <a target=xrefwindow id=d34928e3305 href="http://www.ncbi.nlm.nih.gov/pubmed/24225155">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3308 href="https://doi.org/10.1016/S1470-2045(13)70497-2">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d34928e3318 class=n-a></a>Polgár C, van Limbergen E, Pötter R, <i> et al.</i>: Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). <i>Radiother Oncol.</i> 2010; <b>94</b>(3): 264–73. <a target=xrefwindow id=d34928e3329 href="http://www.ncbi.nlm.nih.gov/pubmed/20181402">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3332 href="https://doi.org/10.1016/j.radonc.2010.01.014">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d34928e3341 class=n-a></a>Correa C, Harris EE, Leonardi MC, <i> et al.</i>: Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. <i>Pract Radiat Oncol.</i> 2017; <b>7</b>(2): 73–9. <a target=xrefwindow id=d34928e3352 href="http://www.ncbi.nlm.nih.gov/pubmed/27866865">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3355 href="https://doi.org/10.1016/j.prro.2016.09.007">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d34928e3364 class=n-a></a>Postoperative radiotherapy for breast cancer: UK consensus statements. 2016. <a target=xrefwindow id=d34928e3366 href="https://www.rcr.ac.uk/system/files/publication/field_publication_files/bfco2016_breast-consensus-guidelines.pdf">Reference Source</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d34928e3375 class=n-a></a>Showalter SL, Petroni G, Trifiletti DM, <i> et al.</i>: A Novel Form of Breast Intraoperative Radiation Therapy With CT-Guided High-Dose-Rate Brachytherapy: Results of a Prospective Phase 1 Clinical Trial. <i>Int J Radiat Oncol Biol Phys.</i> 2016; <b>96</b>(1): 46–54. <a target=xrefwindow id=d34928e3386 href="http://www.ncbi.nlm.nih.gov/pubmed/27511846">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3389 href="https://doi.org/10.1016/j.ijrobp.2016.04.035">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d34928e3398 class=n-a></a>Meattini I, Saieva C, Marrazzo L, <i> et al.</i>: Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. <i>Breast Cancer Res Treat.</i> 2015; <b>153</b>(3): 539–47. <a target=xrefwindow id=d34928e3409 href="http://www.ncbi.nlm.nih.gov/pubmed/26350524">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3412 href="https://doi.org/10.1007/s10549-015-3565-2">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737834422"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3421 class=n-a></a>Wilkinson JB, Chen PY, Wallace MF, <i> et al.</i>: Six-Year Results From a Phase I/II Trial for Hypofractionated Accelerated Partial Breast Irradiation Using a 2-Day Dose Schedule. <i>Am J Clin Oncol.</i> 2018; <b>41</b>(10): 986–91. <a target=xrefwindow id=d34928e3432 href="http://www.ncbi.nlm.nih.gov/pubmed/28787281">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3435 href="https://doi.org/10.1097/COC.0000000000000402">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737834422">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733019036"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3449 class=n-a></a>Latorre JA, Galdós P, Buznego LA, <i> et al.</i>: Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results. <i>J Contemp Brachytherapy.</i> 2018; <b>10</b>(1): 58–63. <a target=xrefwindow id=d34928e3460 href="http://www.ncbi.nlm.nih.gov/pubmed/29619057">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3463 href="https://doi.org/10.5114/jcb.2018.73994">Publisher Full Text </a> | <a target=xrefwindow id=d34928e3467 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5881592">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733019036">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734683706"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3480 class=n-a></a>Jethwa KR, Park SS, Gonuguntla K, <i> et al.</i>: Three-Fraction Intracavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen. <i>Int J Radiat Oncol Biol Phys.</i> 2019; <b>104</b>(1): 75–82. <a target=xrefwindow id=d34928e3491 href="http://www.ncbi.nlm.nih.gov/pubmed/30583041">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3494 href="https://doi.org/10.1016/j.ijrobp.2018.12.025">Publisher Full Text </a> | <a target=xrefwindow id=d34928e3498 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6458060">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734683706">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734771760"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3511 class=n-a></a>Khan AJ, Chen PY, Yashar C, <i> et al.</i>: Three-Fraction Accelerated Partial Breast Irradiation (APBI) Delivered With Brachytherapy Applicators Is Feasible and Safe: First Results From the TRIUMPH-T Trial. <i>Int J Radiat Oncol Biol Phys.</i> 2019; <b>104</b>(1): 67–74. <a target=xrefwindow id=d34928e3522 href="http://www.ncbi.nlm.nih.gov/pubmed/30611839">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3525 href="https://doi.org/10.1016/j.ijrobp.2018.12.050">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734771760">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737142172"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3538 class=n-a></a>Kinj R, Chand ME, Gal J, <i> et al.</i>: Five-year oncological outcome after a single fraction of accelerated partial breast irradiation in the elderly. <i>Radiat Oncol.</i> 2019; <b>14</b>(1): 234. <a target=xrefwindow id=d34928e3549 href="http://www.ncbi.nlm.nih.gov/pubmed/31864391">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3552 href="https://doi.org/10.1186/s13014-019-1448-0">Publisher Full Text </a> | <a target=xrefwindow id=d34928e3556 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6925849">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737142172">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737336187"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3569 class=n-a></a>Hannoun-Lévi JM, Lam Cham Kee D, Gal J, <i> et al.</i>: Accelerated partial breast irradiation in the elderly: 5-Year results of the single fraction elderly breast irradiation (SiFEBI) phase I/II trial. <i>Brachytherapy.</i> 2020; <b>19</b>(1): 90–6. <a target=xrefwindow id=d34928e3580 href="http://www.ncbi.nlm.nih.gov/pubmed/31767533">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3583 href="https://doi.org/10.1016/j.brachy.2019.10.007">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737336187">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736725064"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3596 class=n-a></a>Ferreira AR, Di Meglio A, Pistilli B, <i> et al.</i>: Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. <i>Ann Oncol.</i> 2019; <b>30</b>(11): 1784–95. <a target=xrefwindow id=d34928e3607 href="http://www.ncbi.nlm.nih.gov/pubmed/31591636">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3610 href="https://doi.org/10.1093/annonc/mdz298">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736725064">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736011978"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3624 class=n-a></a>Ward MC, Vicini F, Chadha M, <i> et al.</i>: Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation. <i>Int J Radiat Oncol Biol Phys.</i> 2019; <b>105</b>(2): 296–306. <a target=xrefwindow id=d34928e3635 href="http://www.ncbi.nlm.nih.gov/pubmed/31212043">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3638 href="https://doi.org/10.1016/j.ijrobp.2019.06.014">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736011978">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736343660"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3651 class=n-a></a>Buszek SM, Lin HY, Bedrosian I, <i> et al.</i>: Lumpectomy Plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older With Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database. <i>Int J Radiat Oncol Biol Phys.</i> 2019; <b>105</b>(4): 795–802. <a target=xrefwindow id=d34928e3662 href="http://www.ncbi.nlm.nih.gov/pubmed/31377160">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3665 href="https://doi.org/10.1016/j.ijrobp.2019.07.052">Publisher Full Text </a> | <a target=xrefwindow id=d34928e3669 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7047656">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736343660">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717992027"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3682 class=n-a></a>Blamey RW, Bates T, Chetty U, <i> et al.</i>: Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. <i>Eur J Cancer.</i> 2013; <b>49</b>(10): 2294–302. <a target=xrefwindow id=d34928e3693 href="http://www.ncbi.nlm.nih.gov/pubmed/23523089">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3696 href="https://doi.org/10.1016/j.ejca.2013.02.031">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717992027">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d34928e3709 class=n-a></a>Fisher B, Dignam J, Bryant J, <i> et al.</i>: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. <i>J Natl Cancer Inst.</i> 1996; <b>88</b>(21): 1529–42. <a target=xrefwindow id=d34928e3720 href="http://www.ncbi.nlm.nih.gov/pubmed/8901851">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3723 href="https://doi.org/10.1093/jnci/88.21.1529">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729704785"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3732 class=n-a></a>Brett J, Fenlon D, Boulton M, <i> et al.</i>: Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. <i>Eur J Cancer Care (Engl).</i> 2018; <b>27</b>(1): e12601. <a target=xrefwindow id=d34928e3743 href="http://www.ncbi.nlm.nih.gov/pubmed/27901302">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3746 href="https://doi.org/10.1111/ecc.12601">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729704785">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d34928e3759 class=n-a></a>Badakhshi H, Gruen A, Sehouli J, <i> et al.</i>: The impact of patient compliance with adjuvant radiotherapy: a comprehensive cohort study. <i>Cancer Med.</i> 2013; <b>2</b>(5): 712–7. <a target=xrefwindow id=d34928e3770 href="http://www.ncbi.nlm.nih.gov/pubmed/24403236">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3773 href="https://doi.org/10.1002/cam4.114">Publisher Full Text </a> | <a target=xrefwindow id=d34928e3777 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3892802">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d34928e3787 class=n-a></a>International Agency for Research on Cancer: GLOBOCAN 2012. Estimated cancer Incidence: age-specific tables. </span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d34928e3796 class=n-a></a>Daskivich TJ, Chamie K, Kwan L, <i> et al.</i>: Overtreatment of men with low-risk prostate cancer and significant comorbidity. <i>Cancer.</i> 2011; <b>117</b>(10): 2058–66. <a target=xrefwindow id=d34928e3807 href="http://www.ncbi.nlm.nih.gov/pubmed/21523717">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3810 href="https://doi.org/10.1002/cncr.25751">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d34928e3819 class=n-a></a>Chen RC, Rumble RB, Loblaw DA, <i> et al.</i>: Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. <i>J Clin Oncol.</i> 2016; <b>34</b>(18): 2182–90. <a target=xrefwindow id=d34928e3830 href="http://www.ncbi.nlm.nih.gov/pubmed/26884580">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3833 href="https://doi.org/10.1200/JCO.2015.65.7759">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14267099"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3842 class=n-a></a>Jones CU, Hunt D, McGowan DG, <i> et al.</i>: Radiotherapy and short-term androgen deprivation for localized prostate cancer. <i>N Engl J Med.</i> 2011; <b>365</b>(2): 107–18. <a target=xrefwindow id=d34928e3853 href="http://www.ncbi.nlm.nih.gov/pubmed/21751904">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3856 href="https://doi.org/10.1056/NEJMoa1012348">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14267099">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734213858"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3869 class=n-a></a>Morgan SC, Hoffman K, Loblaw DA, <i> et al.</i>: Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. <i>J Clin Oncol.</i> 2018; JCO1801097. <a target=xrefwindow id=d34928e3877 href="http://www.ncbi.nlm.nih.gov/pubmed/30307776">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3880 href="https://doi.org/10.1200/JCO.18.01097">Publisher Full Text </a> | <a target=xrefwindow id=d34928e3883 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6269129">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734213858">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/7053959"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3896 class=n-a></a>Nguyen PL, Chen MH, Beard CJ: Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. <i>Int J Radiat Oncol Biol Phys.</i> 2010; <b>77</b>(4): 1046–52. <a target=xrefwindow id=d34928e3904 href="http://www.ncbi.nlm.nih.gov/pubmed/19864082">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3907 href="https://doi.org/10.1016/j.ijrobp.2009.06.038">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/7053959">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d34928e3921 class=n-a></a>Denham JW, Steigler A, Lamb DS, <i> et al.</i>: Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. <i>Lancet Oncol.</i> 2011; <b>12</b>(5): 451–9. <a target=xrefwindow id=d34928e3932 href="http://www.ncbi.nlm.nih.gov/pubmed/21440505">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3935 href="https://doi.org/10.1016/S1470-2045(11)70063-8">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d34928e3944 class=n-a></a>McGowan D, Hunt D, Jones C, <i> et al.</i>: Effects of short-term endocrine therapy prior to and during radiation therapy on overall survival in patients with T1b-T2b adenocarcinoma of the prostate and PSA equal to or less than 20: initial results of RTOG 94 – 08. Genitourinary Cancers Symposium (GUCS), San Francisco 2010. Abstract 6, 30653–30673.</span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2558956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e3956 class=n-a></a>Bolla M, de Reijke TM, van Tienhoven G, <i> et al.</i>: Duration of androgen suppression in the treatment of prostate cancer. <i>N Engl J Med.</i> 2009; <b>360</b>(24): 2516–27. <a target=xrefwindow id=d34928e3967 href="http://www.ncbi.nlm.nih.gov/pubmed/19516032">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3970 href="https://doi.org/10.1056/NEJMoa0810095">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2558956">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d34928e3983 class=n-a></a>Bekelman JE, Mitra N, Handorf EA, <i> et al.</i>: Effectiveness of Androgen-Deprivation Therapy and Radiotherapy for Older Men With Locally Advanced Prostate Cancer. <i>J Clin Oncol.</i> 2015; <b>33</b>(7): 716–22. <a target=xrefwindow id=d34928e3994 href="http://www.ncbi.nlm.nih.gov/pubmed/25559808">PubMed Abstract </a> | <a target=xrefwindow id=d34928e3997 href="https://doi.org/10.1200/JCO.2014.57.2743">Publisher Full Text </a> | <a target=xrefwindow id=d34928e4001 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4334776">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d34928e4010 class=n-a></a>Dearnaley D, Syndikus I, Mossop H, <i> et al.</i>: Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(8): 1047–60. <a target=xrefwindow id=d34928e4021 href="http://www.ncbi.nlm.nih.gov/pubmed/27339115">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4024 href="https://doi.org/10.1016/S1470-2045(16)30102-4">Publisher Full Text </a> | <a target=xrefwindow id=d34928e4028 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4961874">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d34928e4037 class=n-a></a>Incrocci L, Wortel RC, Alemayehu WG, <i> et al.</i>: Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(8): 1061–9. <a target=xrefwindow id=d34928e4048 href="http://www.ncbi.nlm.nih.gov/pubmed/27339116">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4051 href="https://doi.org/10.1016/S1470-2045(16)30070-5">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727407499"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4061 class=n-a></a>Catton CN, Lukka H, Gu CS, <i> et al.</i>: Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. <i>J Clin Oncol.</i> 2017; <b>35</b>(17): 1884–90. <a target=xrefwindow id=d34928e4072 href="http://www.ncbi.nlm.nih.gov/pubmed/28296582">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4075 href="https://doi.org/10.1200/JCO.2016.71.7397">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727407499">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d34928e4088 class=n-a></a>Lee WR, Dignam JJ, Amin MB, <i> et al.</i>: Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. <i>J Clin Oncol.</i> 2016; <b>34</b>(20): 2325–32. <a target=xrefwindow id=d34928e4099 href="http://www.ncbi.nlm.nih.gov/pubmed/27044935">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4102 href="https://doi.org/10.1200/JCO.2016.67.0448">Publisher Full Text </a> | <a target=xrefwindow id=d34928e4106 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4981980">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727151256"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4115 class=n-a></a>Shaikh T, Li T, Handorf EA, <i> et al.</i>: Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. <i>Int J Radiat Oncol Biol Phys.</i> 2017; <b>97</b>(4): 722–31. <a target=xrefwindow id=d34928e4126 href="http://www.ncbi.nlm.nih.gov/pubmed/28244407">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4129 href="https://doi.org/10.1016/j.ijrobp.2016.12.034">Publisher Full Text </a> | <a target=xrefwindow id=d34928e4133 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5331910">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727151256">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733814531"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4146 class=n-a></a>Hoffman KE, Voong KR, Levy LB, <i> et al.</i>: Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. <i>J Clin Oncol.</i> 2018; <b>36</b>(29): 2943–9. <a target=xrefwindow id=d34928e4157 href="http://www.ncbi.nlm.nih.gov/pubmed/30106637">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4160 href="https://doi.org/10.1200/JCO.2018.77.9868">Publisher Full Text </a> | <a target=xrefwindow id=d34928e4164 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6804854">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733814531">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d34928e4177 class=n-a></a>Arcangeli G, Saracino B, Arcangeli S, <i> et al.</i>: Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial. <i>J Clin Oncol.</i> 2017; <b>35</b>(17): 1891–7. <a target=xrefwindow id=d34928e4188 href="http://www.ncbi.nlm.nih.gov/pubmed/28355113">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4191 href="https://doi.org/10.1200/JCO.2016.70.4189">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727212469"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4200 class=n-a></a>Droz JP, Albrand G, Gillessen S, <i> et al.</i>: Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. <i>Eur Urol.</i> 2017; <b>72</b>(4): 521–31. <a target=xrefwindow id=d34928e4211 href="http://www.ncbi.nlm.nih.gov/pubmed/28089304">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4214 href="https://doi.org/10.1016/j.eururo.2016.12.025">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727212469">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735839954"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4228 class=n-a></a>Nakamura K, Konishi K, Komatsu T, <i> et al.</i>: Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities. <i>Int J Urol.</i> 2019; <b>26</b>(10): 950–4. <a target=xrefwindow id=d34928e4239 href="http://www.ncbi.nlm.nih.gov/pubmed/31131492">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4242 href="https://doi.org/10.1111/iju.14026">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735839954">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737451781"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4255 class=n-a></a>Wang Z, Ni Y, Chen J, <i> et al.</i>: The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. <i>World J Surg Oncol.</i> 2020; <b>18</b>(1): 42. <a target=xrefwindow id=d34928e4266 href="http://www.ncbi.nlm.nih.gov/pubmed/32093688">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4269 href="https://doi.org/10.1186/s12957-020-01824-9">Publisher Full Text </a> | <a target=xrefwindow id=d34928e4273 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7041271">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737451781">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736753619"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4286 class=n-a></a>Vitzthum LK, Park H, Zakeri K, <i> et al.</i>: Risk of Pelvic Fracture With Radiation Therapy in Older Patients. <i>Int J Radiat Oncol Biol Phys.</i> 2020; <b>106</b>(3): 485–92. <a target=xrefwindow id=d34928e4297 href="http://www.ncbi.nlm.nih.gov/pubmed/31610251">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4300 href="https://doi.org/10.1016/j.ijrobp.2019.10.006">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736753619">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737297065"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4313 class=n-a></a>Couderc AL, Muracciole X, Nouguerede E, <i> et al.</i>: HoSAGE: Sarcopenia in Older Patients before and after Treatment with Androgen Deprivation Therapy and Radiotherapy for Prostate Cancer. <i>J Nutr Health Aging.</i> 2020; <b>24</b>(2): 205–9. <a target=xrefwindow id=d34928e4324 href="http://www.ncbi.nlm.nih.gov/pubmed/32003412">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4327 href="https://doi.org/10.1007/s12603-019-1294-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737297065">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732079710"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4340 class=n-a></a>Schneider BJ, Daly ME, Kennedy EB: Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. <i>J Clin Oncol.</i> 2018; <b>36</b>(7): 710–9. <a target=xrefwindow id=d34928e4348 href="http://www.ncbi.nlm.nih.gov/pubmed/29106810">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4351 href="https://doi.org/10.1200/JCO.2017.74.9671">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732079710">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d34928e4364 class=n-a></a>Chang JY, Senan S, Paul MA, <i> et al.</i>: Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. <i>Lancet Oncol.</i> 2015; <b>16</b>(6): 630–7. <a target=xrefwindow id=d34928e4375 href="http://www.ncbi.nlm.nih.gov/pubmed/25981812">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4378 href="https://doi.org/10.1016/S1470-2045(15)70168-3">Publisher Full Text </a> | <a target=xrefwindow id=d34928e4382 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4489408">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734120948"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4392 class=n-a></a>Shinde A, Li R, Kim J, <i> et al.</i>: Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. <i>Semin Oncol.</i> 2018; <b>45</b>(4): 210–9. <a target=xrefwindow id=d34928e4403 href="http://www.ncbi.nlm.nih.gov/pubmed/30286944">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4406 href="https://doi.org/10.1053/j.seminoncol.2018.06.002">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734120948">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737834554"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4419 class=n-a></a>Miyazaki T, Yamazaki T, Nakamura D, <i> et al.</i>: Surgery or stereotactic body radiotherapy for elderly stage I lung cancer? A propensity score matching analysis. <i>Surg Today.</i> 2017; <b>47</b>(12): 1476–83. <a target=xrefwindow id=d34928e4430 href="http://www.ncbi.nlm.nih.gov/pubmed/28447170">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4433 href="https://doi.org/10.1007/s00595-017-1536-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737834554">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d34928e4446 class=n-a></a>Wang P, Zhang D, Guo XG, <i> et al.</i>: A propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderly. <i>Medicine (Baltimore).</i> 2016; <b>95</b>(52): e5723. <a target=xrefwindow id=d34928e4457 href="http://www.ncbi.nlm.nih.gov/pubmed/28033277">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4460 href="https://doi.org/10.1097/MD.0000000000005723">Publisher Full Text </a> | <a target=xrefwindow id=d34928e4464 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5207573">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d34928e4473 class=n-a></a>Palma D, Visser O, Lagerwaard FJ, <i> et al.</i>: Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. <i>Radiother Oncol.</i> 2011; <b>101</b>(2): 240–4. <a target=xrefwindow id=d34928e4484 href="http://www.ncbi.nlm.nih.gov/pubmed/21775007">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4487 href="https://doi.org/10.1016/j.radonc.2011.06.029">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d34928e4496 class=n-a></a>Schild SE, Mandrekar SJ, Jatoi A, <i> et al.</i>: The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. <i>Cancer.</i> 2007; <b>110</b>(2): 363–8. <a target=xrefwindow id=d34928e4507 href="http://www.ncbi.nlm.nih.gov/pubmed/17542000">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4510 href="https://doi.org/10.1002/cncr.22780">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733535573"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4519 class=n-a></a>Bhalla N, Brooker R, Brada M: Combining immunotherapy and radiotherapy in lung cancer. <i>J Thorac Dis.</i> 2018; <b>10</b>(Suppl 13): S1447–S1460. <a target=xrefwindow id=d34928e4527 href="http://www.ncbi.nlm.nih.gov/pubmed/29951296">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4530 href="https://doi.org/10.21037/jtd.2018.05.107">Publisher Full Text </a> | <a target=xrefwindow id=d34928e4533 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5994496">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733535573">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d34928e4547 class=n-a></a>Formenti SC, Demaria S: Combining radiotherapy and cancer immunotherapy: a paradigm shift. <i>J Natl Cancer Inst.</i> 2013; <b>105</b>(4): 256–65. <a target=xrefwindow id=d34928e4555 href="http://www.ncbi.nlm.nih.gov/pubmed/23291374">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4558 href="https://doi.org/10.1093/jnci/djs629">Publisher Full Text </a> | <a target=xrefwindow id=d34928e4561 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3576324">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d34928e4570 class=n-a></a>Belgioia L, Desideri I, Errico A, <i> et al.</i>: Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review. <i>Crit Rev Oncol Hematol.</i> 2019; <b>133</b>: 163–70. <a target=xrefwindow id=d34928e4581 href="http://www.ncbi.nlm.nih.gov/pubmed/30661652">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4584 href="https://doi.org/10.1016/j.critrevonc.2018.11.009">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735765702"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4593 class=n-a></a>Lin AJ, Roach M, Bradley J, <i> et al.</i>: Combining stereotactic body radiation therapy with immunotherapy: current data and future directions. <i>Transl Lung Cancer Res.</i> 2018; <b>8</b>(1): 107–15. <a target=xrefwindow id=d34928e4604 href="http://www.ncbi.nlm.nih.gov/pubmed/30788240">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4607 href="https://doi.org/10.21037/tlcr.2018.08.16">Publisher Full Text </a> | <a target=xrefwindow id=d34928e4611 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6351396">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735765702">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734066936"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4624 class=n-a></a>Antonia SJ, Villegas A, Daniel D, <i> et al.</i>: Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. <i>N Engl J Med.</i> 2018; <b>379</b>(24): 2342–50. <a target=xrefwindow id=d34928e4635 href="http://www.ncbi.nlm.nih.gov/pubmed/30280658">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4638 href="https://doi.org/10.1056/NEJMoa1809697">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734066936">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d34928e4651 class=n-a></a>Weinmann M, Jeremic B, Bamberg M, <i> et al.</i>: Treatment of lung cancer in elderly part II: small cell lung cancer. <i>Lung Cancer.</i> 2003; <b>40</b>(1): 1–16. <a target=xrefwindow id=d34928e4662 href="http://www.ncbi.nlm.nih.gov/pubmed/12660002">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4665 href="https://doi.org/10.1016/s0169-5002(02)00524-x">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d34928e4674 class=n-a></a>Bayman N, Alam N, Faivre-Finn C: Radiotherapy for lung cancer in the elderly. <i>Lung Cancer.</i> 2010; <b>68</b>(2): 129–36. <a target=xrefwindow id=d34928e4682 href="http://www.ncbi.nlm.nih.gov/pubmed/20079949">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4685 href="https://doi.org/10.1016/j.lungcan.2009.12.004 ">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727730699"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d34928e4695 class=n-a></a>Faivre-Finn C, Snee M, Ashcroft L, <i> et al.</i>: Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. <i>Lancet Oncol.</i> 2017; <b>18</b>(8): 1116–25. <a target=xrefwindow id=d34928e4706 href="http://www.ncbi.nlm.nih.gov/pubmed/28642008">PubMed Abstract </a> | <a target=xrefwindow id=d34928e4709 href="https://doi.org/10.1016/S1470-2045(17)30318-2">Publisher Full Text </a> | <a target=xrefwindow id=d34928e4713 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5555437">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727730699">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 27 May 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-447/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-447/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Experimental and Clinical Biomedical Sciences Biochemistry, Radiotherapy Unit, University of Florence, Florence, Italy<br/> <p> <div class=margin-bottom> Isacco Desideri <br/> <span>Roles: </span> Conceptualization, Data Curation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Viola Salvestrini <br/> <span>Roles: </span> Data Curation, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Lorenzo Livi <br/> <span>Roles: </span> Conceptualization, Supervision, Validation </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-447/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 27 May 2020, 9:447 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.21151.1">https://doi.org/10.12688/f1000research.21151.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Desideri I <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=23282 data-id=21151 data-downloads="" data-views="" data-scholar="10.12688/f1000research.21151.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-447/v1/pdf?article_uuid=f86837c3-78fb-408d-8711-cbe03f5de89f" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.21151.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Desideri I, Salvestrini V and Livi L. Recent advances in de-intensification of radiotherapy in elderly cancer patients [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):447 (<a href="https://doi.org/10.12688/f1000research.21151.1" target=_blank>https://doi.org/10.12688/f1000research.21151.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=21151 id=mobile-track-article-signin-21151 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/21151?target=/articles/9-447/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=23282 /> <input name=articleId type=hidden value=21151 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Roberto Orecchia</strong>, European Institute of Oncology, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Jean Michel Hannoun-L&eacute;vi</strong>, Department of Radiation Oncology, Centre Antoine Lacassagne, University of Cote d'Azur, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 27 May 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-447/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-447/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=67017-62932></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=67018-62931></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-447/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>27 May 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Roberto Orecchia</strong>, European Institute of Oncology, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Jean Michel Hannoun-L&eacute;vi</strong>, Department of Radiation Oncology, Centre Antoine Lacassagne, University of Cote d'Azur, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-447/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-447/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in de-intensification of...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-447/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-447/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-447/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Desideri I et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-447/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-447",
            templates : {
                twitter : "Recent advances in de-intensification of radiotherapy in elderly.... Desideri I et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-447/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in de-intensification of radiotherapy in elderly cancer patients", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in de-intensification of radiotherapy in elderly cancer patients", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/21151/23282")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "23282");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "62931": 0,
                           "62932": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "b0bfa72d-03b8-423e-98c3-29649726e1a1";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-447.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-447.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-447.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-447.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-447.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>